

REFINITIV

DELTA REPORT

10-Q

ZURA BIO LTD

10-Q - MARCH 31, 2024 COMPARED TO 10-Q - SEPTEMBER 30, 2023

The following comparison report has been automatically generated

TOTAL DELTAS	1231
CHANGES	123
DELETIONS	610
ADDITIONS	498

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2023 March 31, 2024

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM
TO

Commission File Number 001-40598

ZURA BIO LIMITED

(Exact name of Registrant as specified in its Charter)

Cayman Islands
(State or other jurisdiction of
incorporation or organization)
1489 W. Warm Springs Rd. #110 Road, Suite 110
Henderson, NV 89014 USA
(Address of principal executive offices)

98-1725736
(I.R.S. Employer
Identification No.)
89014 92037
(Zip Code)

Registrant's telephone number, including area code: (702) 757-6133

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading	Name of each exchange on which registered
	Symbol(s)	
Class A Ordinary Shares	ZURA	The Nasdaq Stock Market LLC (The Nasdaq Capital Market)
Warrants	ZURAW	The Nasdaq Stock Market LLC (The Nasdaq Capital Market)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input type="checkbox"/>	Accelerated <input type="checkbox"/>
		filer
Non-accelerated filer	<input checked="" type="checkbox"/>	Smaller <input checked="" type="checkbox"/>
		reporting
		company
Emerging growth company	<input checked="" type="checkbox"/>	

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of **November 13, 2023** **May 9, 2024**, the registrant had 43,593,678 Class A Ordinary Shares and **6,899,996** **12,809,996** Public Warrants outstanding.

[Table of Contents](#)

Table of Contents

	Page
PART I	FINANCIAL INFORMATION
Item 1.	Financial Statements
	Condensed Consolidated Balance Sheets
	Condensed Consolidated Statements of Operations
	Condensed Consolidated Statements of Changes in Redeemable Noncontrolling Interest, Convertible Preferred Shares, Redeemable Noncontrolling Interest and Shareholders' Equity (Deficit)
	Condensed Consolidated Statements of Cash Flows
	Notes to Condensed Consolidated Financial Statements
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 3.	Quantitative and Qualitative Disclosures About Market Risk
Item 4.	Controls and Procedures
PART II	OTHER INFORMATION
Item 1.	Legal Proceedings
Item 1A.	Risk Factors
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds
Item 3.	Defaults Upon Senior Securities
Item 4.	Mine Safety Disclosures
Item 5.	Other Information

[Table of Contents](#)

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Our forward-looking statements include, but are not limited to, statements regarding our and our management team's expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this Quarterly Report on Form 10-Q may include, for example, statements about:

- Zura Bio Limited ("Zura" , or "the Company")'s success in retaining or recruiting, or changes required in, its officers, key employees or directors; Our expectations regarding our product candidates and their related benefits;
- factors relating to the business, operations Our beliefs regarding potential benefits or limitations of competing products both in development and financial performance of Zura, including, but not limited to Zura's limited operating history; approved;
- Information regarding our vision and strategy;
- The anticipated timing of key events and initiation of our studies and release of clinical data;
- Our expectations regarding the general acceptability and maintenance of our products by regulatory authorities, payors, physicians, and patients;
- Our ability to attract and retain key personnel;
- The accuracy of our future operating expenses, capital requirements, and needs for additional financing;
- Our ability to obtain funding for operations, including funds that may be necessary to complete development of our product candidates;
- The fact that Zura has we have not completed any clinical trials, and has have no products approved for commercial sale;
- the The fact that Zura has we have incurred significant losses since inception, and it expects expect to incur significant losses for the foreseeable future and may not be able to achieve or sustain profitability in the future;
- the The fact that Zura requires we require substantial additional capital to finance its our operations, and if it is we are unable to raise such capital when needed or on acceptable terms, it we may be forced to delay, reduce, and/or eliminate one or more of its our development programs or future commercialization efforts;
- Zura's Our ability to renew existing contracts;
- Zura's Our reliance on third-party contract development manufacturing organizations for the manufacture of clinical materials;
- Our ability to obtain regulatory approval for its our products, and any related restrictions or limitations of any approved products;
- Zura's Our ability to respond to general economic conditions;
- Zura's Our ability to effectively manage its growth effectively; growth;
- the impact of the COVID-19 pandemic;
- competition and competitive Competitive pressures from other companies worldwide in the industries in which Zura operates; companies; and
- litigation Litigation and the ability to adequately protect Zura's our intellectual property rights.

[Table of Contents](#)

These and other factors that could cause actual results to differ from those implied by the forward-looking statements in this Quarterly Report on Form 10-Q are more fully described under the heading "Risk Factors" in the Company's Registration Statement on Form S-4/A 10-K filed with the SEC on February 23, 2023 March 28, 2024. New risk factors emerge from time to time and it is not possible to predict all such risk factors, nor can Zura assess the impact of all such risk factors on the our business of Zura or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements attributable to Zura or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. Zura undertakes no obligations to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

[Table of Contents](#)

In addition, statements of belief and similar statements reflect the beliefs and opinions of Zura on the relevant subject. These statements are based upon information available to Zura as of the date of this Quarterly Report on Form 10-Q, and while Zura believes such information forms a reasonable basis for such statements, such information may be limited or incomplete, and statements should not be read to indicate that Zura has conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you should not put undue reliance on these statements, including, for example, statements about:

- Zura's Our market opportunity;
- Zura's public securities' potential Potential liquidity and trading; trading of our public securities;
- Zura's Our ability to raise financing in the future;
- the Our attraction and retention of qualified directors, officers, employees, and key personnel of Zura; personnel;
- the Our ability of Zura to compete effectively in a highly competitive market;
- the The competition from larger pharmaceutical and biotechnology companies that have greater resources, technology, relationships, and/or expertise;
- the The ability to protect and enhance Zura's our corporate reputation and brand;
- the The impact from future regulatory, judicial, and legislative changes in Zura's our industry;
- Zura's Our ability to obtain and maintain regulatory approval of any of its product candidates;
- Zura's Our ability to research, discover and develop additional product candidates;
- Zura's Our ability to grow and manage growth profitably; growth;
- Zura's Our ability to obtain and maintain intellectual property protection and not infringe on the rights of others;
- Zura's Our ability to execute its business plans and strategy;
- the impact of the COVID-19 pandemic and other similar disruptions in the future; and
- those Those factors set forth in our documents of Zura or JATT Acquisition Corp. ("JATT") filed, or to be filed, with the SEC.

Should one or more of these risks or uncertainties materialize or should any of the assumptions made by the management of Zura prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements.

All subsequent written and oral forward-looking statements concerning Zura or other matters addressed in this Quarterly Report on Form 10-Q and attributable to Zura or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this Quarterly Report on Form 10-Q. Except to the extent required by applicable law or regulations, Zura undertakes no obligation to update these forward-looking statements to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect the occurrence of unanticipated events.

[Table of Contents](#)

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

Zura Bio Limited

Condensed Consolidated Balance Sheets
(In thousands, except **share and per share** data)

	September 30, 2023 (unaudited)	December 31, 2022	March 31, 2024 (unaudited)	December 31, 2023
Assets				
Current assets:				
Cash and cash equivalents	\$ 103,859	\$ 1,567	\$ 89,817	\$ 99,806
Prepaid expenses and other current assets	733	209	657	1,037
Total current assets	104,592	1,776	90,474	100,843
Deferred offering costs	—	3,486		
Property and equipment, net			9	—
Total assets	\$ 104,592	\$ 5,262	\$ 90,483	\$ 100,843
Liabilities, Convertible Preferred Shares, Redeemable Noncontrolling Interest and Shareholders' Equity (Deficit)				
Liabilities, Redeemable Noncontrolling Interest and Shareholders' Equity				
Current liabilities:				
Accounts payable and accrued expenses	\$ 17,012	\$ 4,428	\$ 14,674	\$ 20,302
Note payable	—	7,756		
Research and development license consideration liability	—	2,634		
Total current liabilities	17,012	14,818	14,674	20,302
Private placement warrants	1,950	—	1,596	990
Total liabilities	18,962	14,818	16,270	21,292
Commitments and contingencies (Note 11)				
Convertible preferred shares				
Series A-1 convertible preferred shares, \$0.001 par value, -0- and 13,510,415 shares authorized, issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	—	12,500		
Commitments and contingencies (Note 9)				
Redeemable noncontrolling interest	20,875	10,000	11,663	18,680
Shareholders' Equity (Deficit):				

Preferred Shares, \$0.0001 par value, 1,000,000 and -0- authorized as of September 30, 2023 and December 31, 2022, respectively; -0- issued and outstanding as of September 30, 2023 and December 31, 2022	—	—		
Class A Ordinary Shares, \$0.0001 par value, 300,000,000 authorized, 43,093,685 issued and outstanding as of September 30, 2023; 1,884,649 authorized, 383,480 issued and outstanding as of December 31, 2022	4	—		
Shareholders' Equity:				
Preferred shares, \$0.0001 par value, 1,000,000 authorized as of March 31, 2024, and December 31, 2023; -0- issued and outstanding as of March 31, 2024, and December 31, 2023			—	—
Class A Ordinary shares, \$0.0001 par value, 300,000,000 authorized, 43,593,678 issued and outstanding as of March 31, 2024, and December 31, 2023			4	4
Additional paid-in capital	158,231	—	172,246	162,820
Accumulated deficit	(95,021)	(32,056)	(111,241)	(103,494)
Total Zura Bio Limited shareholders' equity (deficit)	63,214	(32,056)		
Total Zura Bio Limited shareholders' equity			61,009	59,330
Noncontrolling interest	1,541	—	1,541	1,541
Total shareholders' equity (deficit)	64,755	(32,056)		
Total liabilities, convertible preferred shares, redeemable noncontrolling interest and shareholders' equity (deficit)	\$ 104,592	\$ 5,262		
Total shareholders' equity			62,550	60,871
Total liabilities, redeemable noncontrolling interest, and shareholders' equity			\$ 90,483	\$ 100,843

See accompanying notes to unaudited condensed consolidated financial statements.

[Table of Contents](#)

Zura Bio Limited

Condensed Consolidated Statements of Operations
(Unaudited)
(In thousands, except share and per share data)

	For the Three Months Ended		For the Nine Months		For the Period from	For the Three Months Ended	
	September 30,		Ended September 30,		(date of inception) to	March 31,	
	2023	2022	2023	2022	September 30,	2024	2023
Operating expenses:							
Research and development	\$ 3,965	\$ 415	\$ 37,079	\$ 8,000		\$ 3,593	\$ 4,884
General and administrative	6,222	653	14,732	1,814		4,786	2,835
Total operating expenses	10,187	1,068	51,811	9,814		8,379	7,719
Loss from operations	(10,187)	(1,068)	(51,811)	(9,814)		(8,379)	(7,719)
Other expense/(income), net:							
Other expense, net	4	34	7	32			
Other (income)/expense, net:							
Other (income)/expense						(23)	10
Interest income	(815)	—	(816)	—		(1,215)	(1)

Dividend income	(987)	—	(1,392)	—		
Change in fair value of private placement warrants	(119)	—	236	—	606	(177)
Change in fair value of note payable	—	—	2,244	—	—	2,244
Total other expense/(income), net	(1,917)	34	279	32		
Total other (income)/expense, net					(632)	2,076
Loss before income taxes	(8,270)	(1,102)	(52,090)	(9,846)	(7,747)	(9,795)
Income tax benefit	—	—	—	—	—	—
Net loss before redeemable noncontrolling interest	(8,270)	(1,102)	(52,090)	(9,846)	(7,747)	(9,795)
Net loss attributable to redeemable noncontrolling interest	—	—	203	—	—	203
Net loss	(8,270)	(1,102)	(51,887)	(9,846)	(7,747)	(9,592)
Adjustment to Zura subsidiary's preferred stock to redemption	—	—	(203)	—		
Deemed dividend to redeemable noncontrolling interest	—	—	(10,875)	—		
Accretion of redeemable noncontrolling interest to redemption value					—	(203)
Adjustment of redeemable noncontrolling interest from redemption value to carrying value					7,017	—
Net loss attributable to Class A Ordinary Shareholders of Zura	\$ (8,270)	\$ (1,102)	\$ (62,965)	\$ (9,846)	\$ (730)	\$ (9,795)
Net loss per share attributable to Class A Ordinary Shareholders of Zura, basic and diluted	\$ (0.18)	\$ (2.87)	\$ (2.22)	\$ (57.14)	\$ (0.02)	\$ (2.76)
Weighted-average Class A Ordinary Shares used in computing net loss per share attributable to Class A Ordinary Shareholders of Zura, basic and diluted	46,876,344	383,480	28,402,487	172,326	46,914,542	3,551,906

See accompanying notes to unaudited condensed consolidated financial statements.

[Table of Contents](#)

Zura Bio Limited

Condensed Consolidated Statements of Changes in Redeemable Noncontrolling Interest, Convertible Preferred Shares, Redeemable Noncontrolling Interest and Shareholders' Equity (Deficit)

(Unaudited)

(In thousands, except share data)

	Redeemable Noncontrolling Interest		Convertible Preferred Shares ⁽¹⁾		Class A Ordinary Shares ⁽¹⁾		Paid-in Capital	Accumulated Deficit	Noncontrolling interest	Total Shareholders' Equity (Deficit)
	Interest	Amount	Shares	Amount	Shares	Amount	Capital	Deficit	interest	Equity (Deficit)
Balance as of December 31, 2022	\$ 10,000		125,000	\$ 12,500	3,548	\$ —	\$ —	\$ (32,056)	\$ —	\$ (32,056)
Recapitalization	—		13,385,415	—	276,172	—	—	—	—	—
Balance as of December 31, 2022	10,000		13,510,415	12,500	279,720	—	—	(32,056)	—	(32,056)
Issuance of Series A-1 convertible preferred shares as license compensation	—		267,939	2,186	—	—	—	—	—	—
Conversion of Series A-1 convertible preferred shares to Class A Ordinary Shares in connection with Business Combination	—		(13,778,354)	(14,686)	13,778,354	2	14,684	—	—	14,686

Issuance of Class A Ordinary Shares in connection with Business Combination, including PIPE Investment, Forward Purchase Investment, and Backstop Shares, net of \$4.0 million of transaction costs	—	—	—	12,444,081	1	48,350	—	—	48,351
Issuance of Class A Ordinary Shares to settle research and development license consideration liability	—	—	—	550,000	—	4,488	—	—	4,488
Reclassification of public warrant liability to equity	—	—	—	—	—	2,001	—	—	2,001
Issuance of Class A Ordinary Shares in connection with April 2023 Private Placement, net of \$9.8 million of transaction costs	—	—	—	15,041,530	1	54,133	—	—	54,134
Issuance of Pre-Funded Warrants in connection with April 2023 Private Placement	—	—	—	—	—	16,070	—	—	16,070
Issuance of Class A Ordinary Shares to Lilly in connection with 2023 Lilly License	—	—	—	1,000,000	—	7,840	—	—	7,840
Share-based compensation	—	—	—	—	—	10,665	—	—	10,665
Net loss	(203)	—	—	—	—	—	(51,887)	—	(51,887)
Accretion of redeemable noncontrolling interest to redemption value	203	—	—	—	—	—	(203)	—	(203)
Stone Peach Call Right issued to noncontrolling interest	—	—	—	—	—	—	—	1,541	1,541
Deemed dividend to redeemable noncontrolling interest	10,875	—	—	—	—	—	(10,875)	—	(10,875)
Balance as of September 30, 2023	\$ 20,875	—	\$ —	43,093,685	\$ 4	\$158,231	\$ (95,021)	\$ 1,541	\$ 64,755
Balance as of January 18, 2022 (date of inception)	\$ —	—	\$ —	—	\$ —	\$ —	\$ —	\$ —	\$ —
Issuance of Class A Ordinary Shares at inception	—	—	—	108	—	—	—	—	—
Issuance of Series A-1 convertible preferred shares for cash	—	10,808,332	10,000	—	—	—	—	—	—
Issuance of Series A-1 convertible preferred shares for license	—	2,702,083	2,500	—	—	—	—	—	—
Exercise of stock options	—	—	—	383,372	—	—	—	—	—
Share-based compensation	—	—	—	—	—	321	—	—	321
Net loss	—	—	—	—	—	—	(9,846)	—	(9,846)
Balance as of September 30, 2022	\$ —	13,510,415	\$ 12,500	383,480	\$ —	\$ 321	\$ (9,846)	\$ —	\$ (9,525)

7

Table of Contents

	Redeemable		Convertible		Class A		Additional		Total	Redeemable	Convertible Preferred		O	
	Noncontrolling Interest	Preferred Shares ⁽¹⁾	Shares	Amount	Ordinary Shares ⁽¹⁾		Paid-in Capital	Accumulated Deficit	Noncontrolling interest	Shareholders' Deficit	Noncontrolling Interest	Shares ⁽¹⁾		
					Shares	Amount						Shares		Amount
Balance as of June 30, 2023	\$ 20,875	—	\$ —		43,093,685	\$ 4	\$155,654	\$ (86,751)	\$ 1,541	\$ 70,448				
Share-based compensation	—	—	—		—	—	2,577	—	—	2,577				

Zura Bio Limited
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(In thousands)

	For the Nine Months Ended September 30, 2023	For the Period from January 18, 2022 (date of inception) to September 30, 2022	For the Three Months Ended March 31, 2024	2023
Cash flows from operating activities				
Net loss before redeemable noncontrolling interest	\$ (52,090)	\$ (9,846)	\$ (7,747)	\$ (9,795)
Adjustments to reconcile net loss to net cash used in operating activities:				
Research and development acquired license	27,381	7,500		
Anti-dilution share issuance compensation	2,186	—	—	2,186
Share-based compensation expense	5,075	321		
Change in fair value note payable	2,244	—		
Share-based compensation			2,409	180
Change in fair value of share-based payment liability	1,854	—	—	1,854
Change in fair value of note payable			—	2,244
Change in fair value of private placement warrants	236	—	606	(177)
Foreign exchange transaction loss	6	6		
Foreign exchange transaction (gain)/loss			(23)	9
Changes in operating assets and liabilities:				
Prepaid expenses and other current assets	(524)	(211)	380	(213)
Accounts payable and accrued expenses	2,631	637	(607)	455
Net cash used in operating activities	(11,001)	(1,593)	(4,982)	(3,257)
Cash flows from investing activities				
Purchase of property and equipment			(7)	—
Purchase of research and development license	(8,000)	(5,000)	(5,000)	—
Net cash used in investing activities	(8,000)	(5,000)	(5,007)	—
Cash flows from financing activities				
Proceeds from issuance of Series A-1 convertible preferred shares	—	10,000		
Proceeds from issuance of Ordinary Shares in connection with April 2023 Private Placement, net of \$4.2 million of transaction costs	59,724	—		
Settlement of note payable			—	(10,000)
Proceeds from issuance of Class A Ordinary Shares upon Closing of Business Combination	56,683	—	—	56,683
Proceeds from issuance of Pre-Funded Warrants in connection with April 2023 Private Placement	16,070	—		
Settlement of note payable	(10,000)	—		
Payment of deferred transaction costs	(1,184)	(358)	—	(1,030)
Net cash provided by financing activities	121,293	9,642	—	45,653
Net increase in cash and cash equivalents	102,292	3,049		
Net (decrease)/increase in cash and cash equivalents			(9,989)	42,396
Cash and cash equivalents, beginning of period	1,567	—	99,806	1,567
Cash and cash equivalents, ending of period	\$ 103,859	\$ 3,049		
Cash and cash equivalents, end of period			\$89,817	\$ 43,963
Supplemental Disclosure				
Cash paid for taxes	\$ —	\$ —	—	—
Cash paid for interest	\$ —	\$ —	—	—

Supplemental Disclosure of Non-Cash Investing and Financing Activities					
Issuance of Series A-1 convertible preferred shares for license	\$	—	\$	2,500	\$ — \$ —
Conversion of Series A-1 convertible preferred shares for Class A Ordinary Shares	\$	14,686	\$	—	\$ — \$ 14,686
Accrued 2023 Lilly License consideration	\$	10,000	\$	—	
Non-cash transfers to redeemable noncontrolling interest	\$	10,875	\$	—	
Issuance of Class A Ordinary shares for 2023 Lilly License	\$	7,840	\$	—	
Share-based equity issuance costs	\$	5,590	\$	—	
Settlement of research and development license consideration liability	\$	4,488	\$	—	
Transaction costs include in accounts payable and accrued expenses	\$	—	\$	1,553	
Reclassification of deferred offering costs to additional paid-in capital	\$	4,015	\$	—	
Adjustment of redeemable noncontrolling interest from redemption value to carrying value					\$ 7,017 \$ —
Purchase of property and equipment included in accounts payable and accrued expenses					\$ 2 \$ —
Assumption of public and private placement warrants in connection with Business Combination	\$	3,715	\$	—	\$ — \$ 3,715
Reclassification of public warrant liability to equity	\$	2,001	\$	—	\$ — \$ 2,001
Issuance of Call Right to noncontrolling interest	\$	1,541	\$	—	
Settlement of research and development license consideration liability					\$ — \$ 4,488
Transaction costs included in accounts payable and accrued expenses					\$ — \$ 154
Reclassification of deferred offering costs to additional paid-in capital					\$ — \$ 4,015

See accompanying notes to unaudited condensed consolidated financial statements.

98

[Table of Contents](#)

Zura Bio Limited

Notes to Unaudited Condensed Consolidated Financial Statements

(Tabular amounts in thousands, except share and per share data)

1. Organization and Description of Business

Zura Bio Limited, a Cayman Islands exempted company, formerly known as JATT Acquisition Corp (“JATT”), together with its subsidiaries (collectively, the “Company” or “Zura” or “Zura Bio”), is a clinical-stage biotechnology company advancing immunology assets into Phase 2 development programs, including ZB-168, a fully anti-IL7Ra monoclonal antibody, which it has licensed from Pfizer, Inc. (“Pfizer”), as well as torudokimab (ZB-880), a high affinity monoclonal antibody, and ZB-106, tibatuzumab (ZB-106), a bispecific antibody relating to IL-17 and BAFF, which it has licensed from Eli Lilly and Company (“Lilly”). The Company’s accounting predecessor, Zura Bio Limited (herein referred to as “Legacy Zura”), was formed in the United Kingdom (“UK”) on January 18, 2022 (“Inception”).

Business Combination

On March 20, 2023 (the “Closing Date”), the Company consummated the previously announced business combination (the “Business Combination”), pursuant to the terms of a business combination agreement (the “Business Combination Agreement”), dated as of June 16, 2022 (as amended on September 20, 2022, November 14, 2022, and January 13, 2023), by and among JATT, JATT Merger Sub, JATT Merger Sub 2, Zura Bio Holdings Ltd. (“Holdco”), and Legacy Zura. Pursuant to the Business Combination Agreement, (a) before the closing of the Business Combination, Holdco was established as a new holding company of Legacy Zura and became a party to the Business Combination Agreement; and (b) on the Closing, in sequential order: (i) Merger Sub merged with and into Holdco, with Holdco continuing as the surviving company and a wholly owned subsidiary of JATT; (ii) immediately following the Merger, Holdco merged with and into Merger Sub 2, with Merger Sub 2 continuing as the surviving company and a wholly owned subsidiary of JATT; and (iii) JATT changed its name to “Zura Bio Limited”.

The Business Combination has been accounted for as a reverse recapitalization, with Legacy Zura being the accounting acquirer and JATT as the acquired company for accounting purposes. Accordingly, all historical financial information presented in the unaudited condensed consolidated financial statements represent the accounts of Legacy Zura. The shares and net loss per share attributable to ordinary shareholders of Legacy Zura prior to the Closing Date have been retroactively restated as shares reflecting the exchange ratio established in the Business Combination Agreement.

Prior to the Business Combination, JATT's public shares, public warrants, and public units were listed on the New York Stock Exchange ("NYSE") under the symbols "JATT," "JATT.WS," and "JATT.U," respectively. On March 20, 2023, the Company's Class A ordinary shares ("Class A Ordinary Shares") and public warrants began trading on the Nasdaq under the symbols "ZURA" and "ZURAW," respectively. [See Note 3, Recapitalization for additional details.](#)

Emerging Growth Company Status

The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use the extended transition period for complying with new or revised accounting standards, and as a result of this election, the consolidated financial statements may not be comparable to companies that comply with public company Financial Accounting Standards Board ("FASB") standards' effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of an offering or such earlier time that it is no longer an emerging growth company.

Change in Fiscal Year End

On November 18, 2022, the Board of Directors approved a change in the Company's fiscal year end from March 31 to December 31. The Company's 2022 fiscal year began at the Company's inception on January 18, 2022, and ended on December 31, 2022.

The change in fiscal year end also applies retrospectively to all previously issued financial statements for the periods ended March 31, 2022, June 30, 2022, and September 30, 2022.

[Table of Contents](#)

Liquidity

The Company has incurred operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. The Company has an accumulated deficit of \$95.0 million and \$32.1 million as of September 30, 2023 and December 31, 2022, respectively, a net loss of \$8.3 million and \$1.1 million for the three months ended September 30, 2023 and 2022, and a net loss of \$51.9 million and \$9.8 million for the nine months ended September 30, 2023 and the period ended September 30, 2022, respectively. The Company's existing sources of liquidity as of September 30, 2023 includes \$103.9 million in cash and cash equivalents.

Prior to the Business Combination, the Company historically funded operations primarily with issuances of convertible preferred shares and a promissory note. Upon the closing of the Business Combination, the Company received \$56.7 million in net cash proceeds. Additionally, the Company received \$75.8 million in net cash proceeds in connection with April 2023 Private Placement. The Company's cash requirements include, but are not limited to, product manufacturing costs and working capital requirements. The Company expects such operating losses and negative cash flows from operations will continue but has sufficient liquidity to fund its operations over the next twelve months. [no longer be an emerging growth company effective December 31, 2026.](#)

2. Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

The Company's unaudited condensed consolidated financial statements (the "condensed consolidated financial statements") have been prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP") and include the accounts of its consolidated subsidiaries. Other shareholders' interests in the Company's subsidiaries, Z33 Bio, Inc. ("Z33") and ZB17

LLC ("ZB17"), are shown in the condensed consolidated financial statements as redeemable noncontrolling interest and noncontrolling interest, respectively. All intercompany balances and transactions have been eliminated in consolidation. **If necessary, reclassification of amounts previously reported have been made in the accompanying condensed consolidated financial statements in order to conform to current presentation.**

These condensed consolidated financial statements have been prepared in accordance with U.S. GAAP applicable to interim financial statements. These **condensed consolidated** financial statements are presented in accordance with the rules and regulations of the U.S. Securities and Exchange Commission ("SEC") and do not include all disclosures normally required in annual consolidated financial statements prepared in accordance with U.S. GAAP. As such, the information included herein should be read in conjunction with **Legacy Zura's the Company's** consolidated financial statements and accompanying notes as of **December 31, 2022** and for the **period from January 18, 2022 (date of inception) to December 31, 2022** **year ended December 31, 2023** (the "audited consolidated financial statements") that were included in the Company's Form **8-K 10-K** filed with the SEC on **April 6, 2023** **March 28, 2024**. In management's opinion, these unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements **except for the impact of the recapitalization as described in Note 3**, and reflect all adjustments, which include normal recurring adjustments, necessary for the fair statement of the Company's financial position as of **September 30, 2023** **March 31, 2024**, and the results of operations for the three months ended **September 30, 2023** **March 31, 2024**, and 2022 and for the nine months ended **September 30, 2023** and the period ended **September 30, 2022**. **2023**. The results of operations for the **nine three** months ended **September 30, 2023** **March 31, 2024**, are not necessarily indicative of the results to be expected for the full year ending **December 31, 2023** **December 31, 2024**, or any other future interim or annual period.

Significant Accounting Policies

Except for the addition of **the Business Combination**, the addition of public warrants, private placement warrants, **property** and **pre-funded warrants** (collectively, the "Warrants"), the noncontrolling interest in ZB17, and the addition of stock options with market-based performance conditions, **equipment**, there have been no significant changes in the Company's significant accounting policies from those that were disclosed in Note 2, Summary of Significant Accounting Policies, included in the Company's **audited** consolidated financial statements **that were included in the Company's Current Report on Form 8-K 10-K** filed with the SEC on **April 6, 2023** **March 28, 2024**.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the Company's management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions reflected in the condensed consolidated financial statements relate to and include, but are not limited to, the fair value of Class A Ordinary Shares and other assumptions used to measure share-based compensation, the fair value of redeemable noncontrolling interest, **the fair value of share-based consideration transferred**

for acquired assets, the fair value of contingent consideration, the fair value of the private placement warrants, and the fair value of the note payable. public and private placement warrants.

Risks and Uncertainties

The Company is subject to risks common to early-stage companies in the biotechnology industry, including, but not limited to, development by the Company or its competitors of technological innovations, risks of failure of clinical studies, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and ability to transition from preclinical manufacturing to commercial production of products.

The Company's future product candidates will require approvals from the U.S. Food and Drug Administration ("FDA") and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval for any product candidate, it could have a material adverse impact on the Company.

On March 10, 2023, Silicon Valley Bank became insolvent. State regulators closed the bank and the Federal Deposit Insurance Corporation ("FDIC") was appointed as its receiver. The Company held deposits with this bank. As a result of the actions by the FDIC, the Company's insured and uninsured deposits have been restored.

The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of \$250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company's financial condition, results of operations, and cash flows.

Warrants Property and Equipment

As part Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the estimated useful life of the Business Combination, the Company assumed JATT's public warrant each asset. Computer and private placement warrant liabilities. The public warrants were reclassified office equipment are depreciated over three years. Expenditures for repairs and maintenance are recorded to equity following the Business Combination.

As part of the April 2023 Private Placement, the Company sold pre-funded warrants (the "Pre-Funded Warrants") to certain accredited investors. The Pre-Funded Warrants were classified expense as equity instruments.

Classification of the public and pre-funded warrants as equity instruments and the private placement warrants as liability instruments is based on management's analysis of the guidance in ASC 815. The Company measures the private placement warrant liability at fair value each reporting period with the change in fair value recorded as other (expense) income in the condensed consolidated statements of operations. The Company measured the public warrants at the fair value of the equity instruments as of the Closing Date of the Business Combination. The Company measured the pre-funded warrants at the fair value of the equity instruments as of the date of the April 2023 Private Placement. See Note 8 for additional information.

Noncontrolling Interest

During April 2023, the Company's subsidiary, ZB17, issued a share-based payment award to a third party in connection with 2023 Lilly License representing a noncontrolling interest (See Note 6 for additional information). A noncontrolling interest in a subsidiary is considered an ownership interest in a majority-owned subsidiary that is not attributable to the parent. The Company includes noncontrolling interest as a component of total shareholders' equity on the Company's condensed consolidated balance sheet. The option to acquire ZB17 ownership interests do not provide the option-holder with rights to participate in the profits and losses of the subsidiary prior to the exercise of the option. incurred.

12 10

[Table of Contents](#)

Net Loss Per Share

Basic net loss per share is computed by dividing net loss attributable to Class A Ordinary Shareholders by the weighted-average number of Class A Ordinary Shares outstanding including Pre-Funded Warrants, during the period. Diluted net loss per share excludes the potential impact of the Company's convertible preferred shares and options to purchase Class A Ordinary Shares because their effect would be anti-dilutive due to the Company's net loss for the period presented. Since the Company had a net loss in the period presented, basic and diluted net loss per share are the same.

The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share because to do so would be anti-dilutive:

	September 30, 2023	September 30, 2022	March 31, 2024	March 31, 2023
Convertible preferred shares	—	13,510,415		
Shares issuable upon exercise of the Warrants to purchase Class A Ordinary Shares	12,809,996	—	12,809,996	12,809,996
Shares issuable upon exercise of options to purchase Class A Ordinary Shares	5,681,471	383,371	7,108,188	1,941,933
Shares issuable upon exercise of Z33 Series Seed Preferred Shares call option	2,000,000	—		
Restricted share units	2,213,011	—		
Shares issuable upon exercise of Z33 Series Seed Preferred Shares Put Right			2,000,000	—
Restricted Share Units			1,421,473	499,993
Restricted Share Awards			374,995	—

Total	22,704,478	13,893,786	23,714,652	15,251,922
-------	------------	------------	------------	------------

Shares issuable upon the exercise of performance-based share options ("PSOs") are excluded from the calculation of diluted net loss per share until the Company's management deems it probable that the performance conditions will be satisfied.

Recent Accounting Pronouncements

In June 2022, From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, which clarifies or other standard setting bodies and adopted by the guidance of measuring the fair value of equity securities subject to contractual restrictions that prohibit the sale Company as of the equity securities. The Company early adopted this standard specified effective January 1, 2023. The adoption date. Unless otherwise discussed, the impact of this standard did recently issued standards that are not yet effective will not have a material effect impact on our condensed the Company's financial position, results of operations, or cash flows upon adoption.

In November 2023, the FASB issued ASU 2023-07, Segment Reporting ("ASU 2023-07"). ASU 2023-07 requires disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within the segment measure of profit or loss. This guidance will be applied retrospectively and is effective for annual reporting periods in fiscal years beginning after December 15, 2023, and interim reporting periods in fiscal years beginning after December 31, 2024. The Company does not expect implementation of the new guidance to have a material impact on its consolidated financial statements and disclosures.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 requires annual disclosures of specific categories in the rate reconciliation, additional information for reconciling items that meet a quantitative threshold and a disaggregation of income taxes paid, net of refunds. ASU 2023-09 also eliminates certain existing disclosure requirements related disclosures.

3. Recapitalization

As discussed in Note 1, Organization to uncertain tax positions and Description of Business, unrecognized deferred tax liabilities. ASU 2023-09 is effective for the Company beginning with the 2025 Annual Report on the Closing Date, JATT completed the acquisition of Legacy Zura and acquired 100% of Legacy Zura's shares and Legacy Zura received proceeds of \$56.7 million which includes proceeds from issuance of Class A Ordinary Shares upon the consummation of the Business Combination, including the Redemption Backstop shares (as defined below), proceeds from the PIPE investment (as defined below), and proceeds from the Forward Purchase Agreement (as defined below), Form 10-K. Early adoption is permitted. ASU 2023-09 should be applied prospectively. Retrospective adoption is permitted. The Company recorded \$4.0 million of transaction costs, which consisted of legal, accounting, and other professional services directly related to is currently assessing the Business Combination. These costs were included in additional paid-in capital impact this standard will have on the Company's condensed consolidated balance sheet. On the Closing Date, each holder of Legacy Zura's ordinary shares received approximately 108.083 shares of the Company's Class A Ordinary Shares, par value \$0.0001 per share. See Note 7 for additional details of the Company's shareholders' equity (deficit) prior to and subsequent to the Business Combination.

All equity awards of Legacy Zura were assumed by the Company and converted into comparable equity awards that are settled or exercisable for shares of the Company's Class A Ordinary Shares. As a result, each outstanding share option was converted into an option exercisable for the Company's Class A Ordinary Shares based on an exchange ratio of approximately 108.083 and each outstanding restricted share unit was converted into restricted units of the Company that, upon vesting, will be settled for the Company's Class A Ordinary Shares based on an exchange ratio of approximately 108.083.

Each public and private placement warrant of JATT that was unexercised at the time of the Business Combination was assumed by the Company and represents the right to purchase one Class A Ordinary Share upon exercise of such warrant. Refer to Note 2 and Note 8 for further details.

[Table of Contents](#)

The Business Combination was accounted for as a reverse recapitalization with Legacy Zura as the accounting acquirer and JATT as the acquired company for accounting purposes. Legacy Zura was determined to be the accounting acquirer since Legacy Zura's shareholders as a group prior to the Business Combination held the majority voting interest in the combined entity, Legacy Zura's shareholders appointed 4 out of the 7 directors of the combined Board of Directors, Legacy Zura's management holds certain key positions in the management of the combined entity, and Legacy Zura is the largest of the combining entities based on historical operating activity and comprises all of the ongoing operations. Accordingly, all historical financial information presented in these condensed consolidated financial statements represents the accounts of Legacy Zura. Net assets were stated at historical cost consistent with the treatment of

the transaction as a reverse recapitalization of Legacy Zura. The Company's convertible preferred shares and Class A Ordinary Shares prior to the closing of the Business Combination (as defined in Note 1) have been retroactively restated to reflect the exchange ratio of approximately 108.083 established in the Business Combination Agreement. [statements](#).

The number of Class A Ordinary Shares issued and outstanding immediately following the Business Combination on March 20, 2023 was:

	Shares	%
JATT Public shareholders	182,498	0.7 %
Zura shares issued – 2022 Lilly license	550,000	2.0 %
Redemption Backstop	1,301,633	4.8 %
Redemption Backstop Consideration	2,500,000	9.2 %
JATT Founders	3,450,000	12.8 %
PIPE Investment	2,009,950	7.4 %
Forward Purchase Agreement	3,000,000	11.1 %
Legacy Zura Equityholders	14,058,074	52.0 %
Total shares outstanding	27,052,155	100.0 %

PIPE Investment

Concurrently with the execution of the Business Combination Agreement, JATT entered into subscription agreements with certain “accredited investors” (as defined by Rule 501 of Regulation D) (the “PIPE Investors”) on June 16, 2022, as amended on November 25, 2022, (the “Ewon PIPE Subscription Agreement”) and March 13, 2023 (the “Eugene PIPE Subscription Agreement”), pursuant to which the PIPE Investors collectively subscribed for and agreed to purchase an aggregate of 2,009,950 JATT Class A Ordinary Shares at a purchase price of \$10.00 per share for \$20,099,500.

Forward Purchase Agreement and Redemption Backstop

On January 27, 2022, JATT entered into an Amended Forward Purchase Agreement (the “Forward Purchase Agreement”) with two institutional investors (the “FPA Investors”) providing that at the Closing of the Business Combination: (i) the purchasers will purchase an aggregate of 3,000,000 Class A Ordinary Shares at \$10 per share for \$30,000,000; and (ii) the purchase of, in a binding redemption backstop (the “Redemption Backstop”), up to an additional \$15 million of Class A Ordinary Shares in the event that public Class A Ordinary Share redemptions are greater than 90% in connection with the Business Combination (the “Excess Redemptions”). On the Closing Date, FPA Investors purchased 1,301,633 JATT Class A Ordinary Shares at \$10 per share for \$13,016,330. In addition, the FPA Investors were issued an additional 2,500,000 Class A Ordinary Shares (“Redemption Backstop Consideration”) for no additional consideration.

4.3.Fair Value Measurements

The Company measures certain financial assets and liabilities at fair value on a recurring basis. The Company determines fair value based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants, as determined by either the principal market or the most advantageous market. Inputs used in the valuation techniques to derive fair values are classified based on a three-level hierarchy. These levels are:

Level 1: Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;

Level 2: Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and

Level 3: Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.

14 11

[Table of Contents](#)

Level 3: Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.

Financial instruments consist of cash and cash equivalents, prepaid and other current assets, accounts payable and accrued expenses, note payable, and private placement warrants, and research and development license consideration. warrants. The carrying values of the Company's cash, and cash equivalents, prepaid and other current assets, and accounts payable and accrued expenses approximate their fair value due to the short-term maturity of these instruments.

The following table presents information about the Company's financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2023 March 31, 2024, and December 31, 2022 December 31, 2023, and the fair value hierarchy of the valuation techniques utilized.

	September 30, 2023				March 31, 2024			
	Level 1	Level 2	Level 3	Total	Level 1	Level 2	Level 3	Total
Financial assets:								
Cash equivalents	\$ 101,950	\$ —	\$ —	\$ 101,950	\$87,527	\$ —	\$ —	\$87,527
Financial liabilities:								
Private placement warrants	\$ —	\$ 1,950	\$ —	\$ 1,950	\$ —	\$1,596	\$ —	\$ 1,596

	December 31, 2022				December 31, 2023			
	Level 1	Level 2	Level 3	Total	Level 1	Level 2	Level 3	Total
Financial assets:								
Cash equivalents					\$97,913	\$ —	\$ —	\$97,913
Financial liabilities:								
Note payable	\$ —	\$ —	\$ 7,756	\$ 7,756				
Research and development license consideration	\$ —	\$ —	\$ 2,634	\$ 2,634				
Private placement warrants					\$ —	\$ 990	\$ —	\$ 990

There were no transfers into or out of Level 1, Level 2, or Level 3 during the three and nine months ended September 30, 2023 and the period ended December 31, 2022 March 31, 2024.

Note payable

The On December 8, 2022, the Company elected received \$7.6 million in net proceeds from the fair value option to account for its Note payable issuance of a promissory note (the "Note") issued to Hydra, LLC (see Note 10) ("Hydra") with a face amount of \$8.0 million. The fair value of the Note payable at issuance was measured as the cash proceeds from the Note. The fair value of the Note payable subsequent to issuance was estimated using the probability-weighted expected return method ("PWERM"), whereby the total settlement obligation under the Note was determined based repaid on March 20, 2023, upon the amounts payable to Hydra under various scenarios. The PWERM's output is determined based on inputs not observable in the market, which represented a Level 3 measurement within the fair value hierarchy. The PWERM contemplated three scenarios: i) the Company consummates the Business Combination without triggering an event consummation of default, ii) the Company triggers an event of default, and consummates the Business Combination, and iii) the Company does not consummate the Business Combination. The settlement value of each scenario was determined using a discounted cash flow model. Significant estimates in Company elected to account for the cash flow model include the discount rate and time to repayment. As of December 31, 2022, the weighted average discount rate was 9.0%, and the weighted average time to repayment was 0.6 years, each weighted by the probability of the scenario. Note at fair value. Upon the Closing Date of the Business Combination, the Note was remeasured to the settlement value and subsequently repaid for a total of \$10.0 million. The following table provides a summary of changes in the estimated fair value of the Note:

	For the Nine Months Ended September 30, 2023
Balance at December 31, 2022	\$ 7,756
Remeasurement of the Note to settlement value upon the Closing of the Business Combination	2,244
Settlement of the Note	(10,000)
Balance at September 30, 2023	\$ —

The Company recorded a loss on remeasurement of the Note of \$2.2 million \$2.2 million for the nine three months ended September 30, 2023 March 31, 2023 within change in fair value of note payable on in the condensed consolidated statement of operations.

[Table](#) [The Note was no longer outstanding as of Contents](#) March 31, 2024 and December 31, 2023.

Research and development license consideration

As consideration for the 2022 Lilly License (see Note [6](#) [5](#)), Lilly agreed to receive either 550,000 Zura Class A Ordinary Shares upon the closing of the Business Combination (subject to certain lock-up provisions) or 4,702,867 shares of Z33 Series Seed Preferred Shares (the subsidiary redeemable preferred shares) if the Business Combination was not consummated. [As of December 31, 2022, the](#) [The](#) arrangement was liability classified and remeasured at fair value at each reporting date (the research and development license consideration liability). [The fair value of the research and development license consideration liability was estimated using the PWERM, whereby the total settlement obligation was determined based upon the fair value of the JATT Class A Ordinary Shares, the Z33 Series Seed Preferred Shares, and the probability of the consummation of the Business Combination. As certain of the inputs to the PWERM are not observable in the market, the research and development license consideration liability represented a Level 3 measurement within the fair value hierarchy. As of December 31, 2022, the fair value of JATT Class A Ordinary Shares was determined to be \\$7.66 per share, a discount to the trading price due to the shares being subject to a lock-up provision. As of December 31, 2022, the fair value of Z33 Series Seed Preferred Shares was determined to be \\$0.15 per share.](#)

Upon the Closing Date of the Business Combination, the liability was remeasured to its settlement value and subsequently settled through the issuance of 550,000 Class A Ordinary Shares of Zura. The aggregate fair value of the Class A Ordinary Shares of Zura issued to Lilly was determined to be \$4.5 million, or \$8.16 per share. The [following table provides a summary of changes in the estimated fair value of the liability:](#)

	For the Nine Months Ended September 30, 2023
Balance at December 31, 2022	\$ 2,634
Remeasurement of the liability to settlement value upon the Closing of the Business Combination	1,854
Settlement of the liability	(4,488)
Balance at September 30, 2023	\$ —

[The](#) Company recorded a loss on the remeasurement of the research and development license consideration liability of \$1.9 million for the [nine](#) [three](#) months ended [September 30, 2023](#) [March 31, 2023](#) within research and development [on](#) [in](#) the condensed consolidated [statement](#) [statements](#) of operations. [The research and development license consideration liability was no longer outstanding as of March 31, 2024 and December 31, 2023.](#)

[Table of Contents](#)

Private Placement Warrants

As of [September 30, 2023](#) [March 31, 2024](#), the Company has private placement warrants [assumed in connection with the Business Combination](#) (see Note [8](#) [7](#)). Such warrants are measured at fair value on a recurring basis. Because the transfer of private placement warrants to non-permitted transferees would result in the private placement warrants having substantially the same terms as the public warrants, the Company determined that the fair value of each private placement warrant is consistent with that of a public warrant. Accordingly, the private placement warrants are classified as Level 2 financial instruments. The following table provides a summary of changes in the estimated fair value of the private placement warrants:

Balance at December 31, 2022	\$ —
Assumption of private placement warrants	1,714

Change in fair value	(177)
Balance at March 31, 2023	1,537
Change in fair value	532
Balance at June 30, 2023	\$ 2,069
Change in fair value	(119)
Balance at September 30, 2023	\$ 1,950

	For the Three Months Ended March 31, 2024
Balance at December 31, 2023	\$ 990
Change in fair value	606
Balance at March 31, 2024	\$ 1,596

The Company recorded a **gain** from the change in fair value of the private placement warrants of **\$0.1 million** **\$0.6 million** and a **gain** from change in fair value of the private placement warrants of **\$0.2 million** for the three months ended **September 30, 2023** **March 31, 2024** and a **loss** of **\$0.2 million** for the nine months ended **September 30, 2023**, **2023**, respectively, within change in fair value of private placement warrants on the condensed consolidated **statement** **statements** of operations.

16

[Table of Contents](#)

5.4.Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses is comprised of the following as of **September 30, 2023** **March 31, 2024** and **December 31, 2022** **December 31, 2023**:

	September 30, 2023	December 31, 2022	March 31, 2024	December 31, 2023
Accrued 2023 Lilly License costs			\$ 5,000	\$ 10,000
Accrued research and development costs			7,246	6,091
Accounts payable	\$ 1,645	\$ 2,010	1,485	2,749
Accrued offering costs	—	655		
Accrued payroll	358	260		
Accrued 2023 Lilly License costs	10,000	—		
Accrued legal costs	133	308		
Accrued research and development costs	3,833	490		
Accrued bonus	745	141	390	1,201
Other accrued expenses	121	113	553	261
Accrued consulting fees	177	451		
Total accounts payable and accrued expenses	\$ 17,012	\$ 4,428	\$ 14,674	\$ 20,302

Comparative figures have been reclassified to conform with current period presentation.

6.5.License Agreements

Pfizer

On March 22, 2022, the Company entered into a license agreement and a Series A-1 Subscription and Shareholder's Agreement (collectively, the "Pfizer Agreement") with Pfizer. Under the Pfizer Agreement, the Company acquired a license for a compound initially developed by Pfizer, in exchange for **\$5.0 million** in cash and 2,702,083 shares (as adjusted by the exchange ratio established in the Business Combination Agreement) of the Company's Series A-1 convertible preferred shares, representing a 20% interest in the Company. In accordance with ASC 805, the Pfizer Agreement is accounted for as an asset

acquisition as substantially all of the \$7.5 million value transferred to the Company was allocated to in-process research and development. On the acquisition date, the compound licensed had not yet received regulatory approval and the in-process research and development did not have an alternative use.

In addition to the consideration transferred on March 22, 2022, the Company is obligated to make 12 11 future development and regulatory milestone payments aggregating up to \$70.0 million and sales milestone payments up to an aggregate of \$525.0 million based on respective thresholds of net sales of products (developed from the licensed compound) (the "Products"). In further consideration for the license, the Company will also pay an annual earned royalty at a marginal royalty rate in the mid-single digits to low double digits (less than 20%), based on thresholds of net sales of Products. Royalties are payable on a country-by-country basis for a certain period of years or upon the later expiration of regulatory exclusivity of the Company's Products in a country.

The Company is also subject to a potential multi-million dollar transaction payment if, within a certain period the Company has (a) certain changes in control, excluding an initial public offering or any business combination where the securities of the Company are listed on a stock exchange (e.g., a transaction with a special purpose acquisition company), or (b) the Company sublicenses or divests of its rights to the Products.

The Pfizer Agreement also has an anti-dilution provision to allow Pfizer to maintain an 18% interest. Company recognized the first \$1.0 million development milestone as a component of research and development in the Company consolidated statement of operations during the year ended December 31, 2023. This amount due is included in accounts payable and accrued expenses on the condensed consolidated balance sheet as detailed in Note 7. Immediately prior to the Closing Date of the Business Combination, additional share options and restricted share units were issued to certain employees, executives, and directors that would result in the dilution of Pfizer's ownership in the Company. In accordance with the anti-dilution provision of the Pfizer Agreement, Pfizer was issued additional Series A-1 convertible preferred shares upon the closing of the Business Combination that were immediately converted to 267,939 Class A Ordinary Shares. In accordance with ASC 718, the Company recognized expense related to these Class A Ordinary Shares based on their grant date fair value. Following the Business Combination, the anti-dilution provision is no longer in effect.

As of September 30, 2023, the March 31, 2024. The Company does not owe any other amounts under the Pfizer Agreement. Agreement as of March 31, 2024.

17 13

[Table of Contents](#)

Lonza

In July 2022, the Company entered into a license agreement (the "Lonza License") with Lonza Sales AG ("Lonza") for a worldwide non-exclusive license for Lonza's gene expression system in exchange for varying considerations depending on a number of factors such as whether the Company enters further into manufacturing agreements with Lonza or with a third party, and whether the Company enters into sublicense agreements with third parties (including up to middle six-figure annual payments per sublicense upon commencement of a sublicense, as well as royalties of up to low-single digit percentages of net sales of certain products over a commercially standard double-digit multi-year term). The Lonza License will remain in effect until terminated. The Company is free to terminate the Lonza License at any time upon 60 days' notice, with or without cause. Lonza may terminate the Lonza License for cause upon a breach by the Company or for other commercially standard reasons.

During October 2023, the Company began drug substance manufacturing with a third party. As a result of manufacturing with a third party other than Lonza, under the terms of the Lonza License the first annual milestone payment of \$0.4 million became due and was paid during the three months ended March 31, 2024.

2022 Lilly License

On December 8, 2022, the Company's consolidated subsidiary, Z33 Bio Inc. ("Z33"), entered into a license agreement (the "2022 Lilly License") with Lilly pursuant to which Lilly granted Z33 an exclusive (even as to Lilly), royalty-bearing global license to develop, manufacture, and commercialize certain intellectual property owned by Lilly relating to its IL-33 compound. As consideration, the Company paid Lilly an upfront fee of \$7.0 million.

As consideration for the 2022 Lilly License, Lilly agreed to receive either 550,000 Class A Ordinary Shares upon the closing of the Business Combination (subject to certain lock-up provisions) or 4,702,867 shares of Z33 Series Seed Preferred Shares (the subsidiary redeemable preferred shares) if the Business Combination was not consummated. The obligation to issue shares represents contingent consideration and is classified as a liability on the consolidated balance sheet (research and development license consideration liability) as of December 31, 2022. The liability is measured at fair value on the acquisition date and remeasured to fair value at each reporting date. Upon the Closing Date of the Business Combination, the Company issued Lilly 550,000 Class A Ordinary Shares at an aggregate fair value of \$4.5 million.

The acquisition was accounted for as an asset acquisition as substantially all of the fair value of the assets acquired is concentrated in a group of similar identifiable IPR&D assets (as defined below). On the acquisition date, the compound licensed had not yet received regulatory approval and the in-process research and development did not have an alternative use. Accordingly, the Company expensed the entire cost of the 2022 Lilly License as a component of research and development in the consolidated statement of operations during the period ended December 31, 2022.

As a finder's fee in connection with arranging the acquisition, Z33 issued to Stone Peach Properties, LLC ("Stone Peach") 4,900,222 shares of Z33 Series Seed Preferred Shares, which is included in the measurement of the cost of the acquired asset. Zura has the right, but not the obligation to purchase up to 50% of the Series Seed Preferred Shares issued to Stone Peach at a price per share of \$2.448869 for a period of two years from the date of the agreement. agreement (the "Call Option"). Stone Peach has the right, but not the obligation to sell up to 50% of the Series Seed Preferred Shares issued to Stone Peach to Zura for a price per share of \$2.040724. \$2.040724 (the "Put Option"). Stone Peach may exercise its option at any time between the first anniversary and the second anniversary of the transaction. In April 2023, the Company agreed to, within six months of April 24, 2023, exercise its call option Call Option on 50% of the Z33 Series Seed Preferred Shares previously issued to Stone Peach. The Company agreed to settle its call option Call Option by issuing 2,000,000 Class A Ordinary Shares. See Note 12 for further information. The In November 2023, the Company and Stone Peach are renegotiating amended the terms of the agreement, voiding the Company's obligation to exercise its Call Option, and instead reverting the Company's rights and obligations under the Call Option back to that of the call option.

In original agreement. Stone Peach, in addition to the consideration transferred on December 8, 2022, existing Put Option, was granted the right, but not the obligation to sell up to 50% of the Series Seed Preferred Shares issued to Stone Peach to Zura in exchange for 2,000,000 Class A Ordinary Shares (the "Put Right"). Stone Peach may exercise its Put Option and Put Right at any time between April 24, 2024 and April 24, 2028 under the new agreement.

The Company is obligated to pay \$3.0 million to Lilly under the 2022 Lilly License upon the completion of a financing by the Company with gross proceeds exceeding \$100 million. The Company is further obligated to make 10 commercial, development and regulatory milestone payments up to an aggregate of \$155.0 million and sales milestone payments up to an aggregate of \$440.0 million based on respective thresholds of net sales of products developed from the licensed compound. The Company will also pay an annual earned royalty to Lilly at a marginal royalty rate between in the mid-single to low-double digits (less than 20%), with increasing rates based on Net Sales net sales in the respective calendar year, based on a percentage of sales within varying thresholds for a certain period of the year. The Company will account for these contingent payments when they become due. As of September 30, 2023 March 31, 2024, none of the contingent payments were due.

2023 Lilly License

On April 26, 2023, the Company's newly-formed subsidiary ZB17 LLC ("ZB17") entered into a license agreement (the "2023 Lilly License" and, together with the 2022 Lilly License, the "Lilly Licenses") with Lilly, for an exclusive license to develop, manufacture and commercialize a certain bispecific antibody relating to IL-17 and BAFF ("ZB-106") in exchange for an upfront payment consisting

18

[Table of Contents](#)

of \$5.8 million as well as 1,000,000 Class A Ordinary Shares issued at a fair value of \$7.84 per Class A Ordinary Share. In addition, ZB17 will make made a payment of \$5.0 million upon to Lilly during the three months ended March 31, 2024 in connection with the receipt of certain know-how, data, information and materials that Lilly is was required to provide under the license agreement.

The acquisition was accounted for as an asset acquisition as substantially all of the fair value of the assets acquired is concentrated in a group of similar identifiable IPR&D assets. On the acquisition date, the compound licensed had not yet received regulatory approval and the in-process research and development did not have an alternative use. Accordingly, the Company expensed the entire cost of the 2023 Lilly License as a component of research and development in the condensed consolidated statement of operations during the nine months ended September 30, 2023.

As a finder's fee for arranging the acquisition of the 2023 Lilly License, ZB17 granted to Stone Peach the right, but not the obligation, to purchase 4.99% of the fully diluted equity of ZB17 for \$1.0 million (the "Stone Peach Call Right"). The Stone Peach Call Right is not exercisable until after the last patient is dosed in any single next clinical trial with ZB-106 and expires one year from the date of first indication approval for ZB-106 by the FDA or the European Medicines Agency ("EMA"). The Company recognized the Stone Peach Call Right at a grant-date fair value of \$1.5 million as a component of research and development in the condensed consolidated statement of operations during the nine months ended September 30, 2023. The Stone Peach Call Right represents

14

[Table of Contents](#)

noncontrolling interest in the Company's subsidiary, ZB17.

As of September 30, 2023, March 31, 2024, and December 31, 2022, December 31, 2023, the noncontrolling interest balance was \$1.5 million and \$0-, respectively.

As additional consideration, Stone Peach will receive receives annual payments first of \$0.6 million, and increasing by 10% annually, so long as the Company maintains its license for ZB-106 and beginning on May 1, 2023, May 1st of each year. The Company will account for these annual payments when as they become due. The Company recognized the first \$0.6 million annual payment as a component of research and development in the condensed consolidated statement of operations during the nine months ended September 30, 2023.

As a finder's fee for arranging the acquisition of the 2023 Lilly License, the Company agreed to make a one-time milestone payment of \$5.0 million to BAFFX17, Ltd ("BAFFX17") upon the occurrence of either: (i) a change of control transaction, (ii) the closing of an issuance of equity or equity-linked securities by the Company of at least \$100.0 million, (iii) the consummation of a sale of assets resulting in net proceeds in excess of \$100.0 million, or (iv) the Company's fully diluted shares outstanding exceed 52,500,000 shares (on a split adjusted basis). As the Company's fully diluted shares outstanding exceeded 52,500,000 shares prior to September 30, 2023, December 31, 2023, the \$5.0 million fee was recorded in accounts payable and accrued expenses in the condensed consolidated balance sheet as of September 30, 2023, March 31, 2024 and within research and development in the condensed consolidated statement of operations for the nine months ended September 30, 2023, December 31, 2023.

In addition to the consideration transferred during the nine months ended September 30, 2023, the The Company is obligated to make 4 development milestone payments to Lilly up to an aggregate of \$155.0 million, and sales milestone payments up to an aggregate of \$440 million based on respective thresholds of net sales of products developed from ZB-106, sales. The Company is also obligated to pay Lilly over a multi-year period (twelve years, or upon the later expiration of regulatory exclusivity of ZB-106 in a country) an annual earned royalty at a marginal royalty rate in the mid-single digits to low-double digits, with increasing rates depending on net sales in the respective calendar year, based on a percentage of sales within varying thresholds for a certain period of years. The Company is also obligated to pay BAFFX17 a fee equal to 3% of any milestone or royalty payments due to Lilly pursuant to the terms of either the 2022 Lilly License and the 2023 Lilly License with Lilly. Upon receiving written approval from the FDA, EMA, or similar regulatory authority of the Investigational New Drug ("IND") and commencement and the commencement of a clinical trial in the applicable jurisdiction for ZB-106, Stone Peach will also receive a one-time payment of \$4.5 million. Stone Peach will also receive a one-time milestone payment of \$25 million upon either (i) certain equity-related transactions, or (ii) the receipt of regulatory approval from the applicable regulatory authority for any new indication in the applicable jurisdiction. Furthermore, Stone Peach was granted a royalty of 2% of the aggregate net sales of any products developed from the Compound, licensed compound. The Company will account for these contingent payments when they become due. As of September 30, 2023, March 31, 2024, none of the contingent payments were due.

WuXi Biologics License

In July 2023, the Company entered into a cell line license agreement (the "Cell Line License Agreement" Agreement) with WuXi Biologics and its Affiliates ("WuXi Biologics" Biologics). The Cell Line License Agreement provides the Company with a non-exclusive, worldwide, sublicensable license to for certain of WuXi Biologics's know-how, Biologics' know - how, cell line, and biological materials (the "WuXi WuXi Biologics Licensed Technology" Technology) to manufacture, have manufactured, use, sell and import certain products produced through the use of the cell line licensed by WuXi Biologics under the Cell Line License Agreement (the "WuXi WuXi Biologics Licensed Products" Products). In consideration for the license, the

[Table of Contents](#)

Company agreed to pay WuXi Biologics a non-refundable license fee of \$150,000. Additionally, if If the Company manufactures all of its commercial supplies of bulk drug product for WuXi Biologics Licensed Products with a manufacturer other than WuXi Biologics or its affiliates, the Company is required to make royalty payments to WuXi Biologics in an amount equal to a fraction of a single digit percentage of global net sales of WuXi Biologics Licensed Products manufactured by a third-party manufacturer (the "Royalty" Royalty). If the Company manufactures part of its commercial supplies of the WuXi Biologics Licensed Products with WuXi Biologics or its affiliates, then the Royalty will be reduced accordingly on a pro rata basis. The Cell Line License Agreement will continue indefinitely unless terminated (i) by the Company upon three months months prior written notice and its payment of all undisputed amounts due to WuXi Biologics through

the effective date of termination, (ii) by WuXi Biologics for a material breach by the Company that remains uncured for 30 days after written notice, or (iii) by WuXi Biologics if the Company fails to make a payment and such failure continues for 30 days after receiving notice of such failure.

7.6.Convertible Preferred Shares and Shareholders' Equity (Deficit)

Prior to the Business Combination, Legacy Zura was authorized to issue Ordinary Shares and Series A-1 convertible preferred shares. The outstanding Ordinary Shares and Series A-1 convertible preferred shares of Legacy Zura are presented on the consolidated balance sheet and on the statement of changes in convertible preferred shares, redeemable noncontrolling interest and shareholders' deficit for the annual period ended December 31, 2022.

Business Combination

Immediately prior to the Closing Date of the Business Combination, Pfizer was issued additional Series A-1 convertible preferred shares upon the closing of the Business Combination that were immediately converted to 267,939 Class A Ordinary Shares. The shares were issued in accordance with the anti-dilution provision of the Pfizer Agreement.

On the Closing Date and in accordance with the terms and subject to the conditions of the Business Combination, each Class A Ordinary Share of Legacy Zura, par value \$0.001 per share, Series A-1 convertible preferred share, outstanding option (whether vested or unvested), and restricted share unit (whether vested or unvested) were canceled and converted into a comparable number of awards that

15

[Table of Contents](#)

consisted of either the rights to receive or acquire the Company's Class A Ordinary Shares, par value \$0.0001 per share, as determined by the exchange ratio pursuant to the Business Combination Agreement. The exchange ratio is approximately 108.083.

On March 16, 2023, in connection with the closing of the Business Combination and effective upon the Closing Date, the Company authorized 300,000,000 Class A Ordinary Shares, par value of \$0.0001 and 1,000,000 preferred shares, par value of \$0.0001.

April 2023 Private Placement

On April 26, 2023, the Company entered into its second PIPE subscription agreement (the "April 2023 Private Placement") with certain accredited investors (the "Subscribers"), whereby the Company issued 15,041,530 Class A Ordinary Shares par value \$0.0001 per share and pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 3,782,000 Class Reserved for Issuance

A Ordinary Shares. Each Class A Ordinary Share was sold at a price summary of \$4.25 per Class A Ordinary Share and each Pre-Funded Warrant was sold at a price shares reserved for issuance as of \$4.249 per Pre-Funded Warrant for an aggregate purchase price of \$80.0 million. See Note 8 for further information on the Pre-Funded Warrants. March 31, 2024 is summarized below:

	March 31, 2024
Shares issuable upon exercise of options to purchase Class A Ordinary Shares	7,108,188
Restricted Share Units	1,442,473
Shares issuable upon exercise of warrants to purchase Class A Ordinary Shares	16,591,996
Shares issuable upon exercise of Z33 Put Right	2,000,000
Shares available for grant under Equity Incentive Plan	2,824,119
Shares available for grant under ESPP	4,029,898
Total shares reserved for issuance	33,996,674

Each Series A-1 convertible preferred share is convertible, at the option of the holder thereof, at any time after the date of issuance of such share, into such number shares of the Company's Ordinary Shares, subject to adjustment.

Each Series A-1 convertible preferred share will automatically be converted into a share of the Company's Ordinary Shares, subject to adjustment, immediately upon the occurrence of an initial public offering with a gross aggregate subscription with respect to new Ordinary Shares of greater than \$50.0 million. The

Ordinary Shares resulting from this conversion will rank pari passu with the existing Ordinary Shares at the time of conversion.

[Table of Contents](#)

Anti-Dilution

If the Company issues equity securities, other than pursuant to a share option plan, the Company shall issue such number of Series A-1 convertible preferred shares to Pfizer as necessary to maintain Pfizer's ownership interest of 18%, until the Company raises in excess of \$30.0 million in equity, where any capital raised above this threshold is not subject to anti-dilution.

Dividends

The holders of shares of Series A-1 convertible preferred shares are entitled to receive dividends, of profits available for distribution as determined by the Company's board of directors with the consent of the majority of the shareholders, payable on a pro rata, pari passu basis. No dividends have been declared by the Company's board of directors.

Liquidation

In the event of any voluntary or involuntary liquidation or return of capital (other than a conversion, redemption or purchase of shares) of the Company, the holders of the Series A-1 convertible preferred shares are entitled to receive a liquidation preference prior to any distribution to the holders of Ordinary Shares in the amount \$131 per share.

Voting Rights

The holders of the Series A-1 convertible preferred shares are entitled to one vote per share, unless the Series A-1 shares are convertible into a greater number of Ordinary Shares or the holders of Series A-1 convertible preferred shares are entitled to any anti-dilution shares, in which case the holders of Series A-1 convertible preferred shares are entitled to the number of votes that the holder would be entitled upon conversion to Ordinary Shares or after the issuance of the anti-dilution shares, respectively.

Redemption Rights

The Series A-1 convertible preferred shares are not mandatorily redeemable at the option of the holder.

As of September 30, 2023, no convertible preferred shares were issued and outstanding.

8.7. Warrants

As in connection with the accounting acquirer, Zura Bio is deemed to have Business Combination, the Company assumed 5,910,000 private placement warrants to purchase Class A Ordinary Shares that were held by JATT Ventures, L.P. (the "Sponsor") at an exercise price of \$11.50 and 6,899,996 public warrants to purchase Class A Ordinary Shares that were held by JATT's public shareholders at an exercise price of \$11.50, shareholders. The public and private placement warrants Warrants will expire five years after the completion of the Business Combination, or earlier upon redemption or liquidation.

As of March 31, 2024, no warrants have been exercised or redeemed.

Public Warrants

The public warrants became exercisable into Class A Ordinary Shares commencing 30 days after the Business Combination and expire five years from the date of the Business Combination, or earlier upon redemption or liquidation. Each warrant entitles the holder to purchase one share of the Company's Class A Ordinary Shares at a price of \$11.50 per share, subject to certain adjustments.

The Company may redeem, with 30 days written notice, each whole outstanding public warrant for cash at a price of \$0.01 per warrant if the Reference Value (as defined below) equals or exceeds \$18.00 per share, subject to certain adjustments. The warrant holders have the right to exercise their outstanding warrants prior to the scheduled redemption date at \$11.50 per share, subject to certain adjustments. If the Company calls the public warrants for redemption, the Company will have the option to require all holders that wish to exercise the Public Warrants to do so on a "cashless basis", as described in the warrant

agreement. For purposes of the redemption, "Reference Value" shall mean the last reported sales price of the Company's Class A Ordinary Shares for any twenty trading days within the thirty trading-day period ending on the third trading day prior to the date on which notice of the redemption is given.

Private Placement Warrants

The private placement warrants were are identical to the public warrants, except that the private placement warrants are not transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions. Additionally,

21

[Table of Contents](#)

the private placement warrants are exercisable on a cashless basis and are non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the private placement warrants are held by someone other than the initial purchasers or their permitted transferees, then such warrants will be redeemable by the Company and exercisable by the warrant holders on the same basis as the public warrants.

Pre-Funded Warrants

In connection with the April 2023 Private Placement, the Company sold to accredited investors Pre-Funded Warrants to purchase up to 3,782,000 Class A Ordinary Shares at a price of \$4.249 per Pre-Funded Warrant for an aggregate purchase price of approximately \$16.1 million. Each Pre-Funded Warrant has an exercise price of \$0.001 per Class A Ordinary Share and is exercisable for one Class A Ordinary Share at any time or times on or after April 26, 2023, until exercised in full.

As 16

[Table of Contents](#)

The following table presents the number of warrants outstanding, their exercise price, and expiration dates as of March 31, 2024:

Warrants Issued	Exercise Price	Expiration Date
6,899,996	\$ 11.50	March 2028
5,910,000	\$ 11.50	March 2028
3,782,000	\$ 0.001	N/A

, no Warrants have been exercised or redeemed.

9.8. Share-based Compensation

On June 8, 2022, Legacy Zura's board of directors approved two stock option plans, the UK Plan (the "UK Plan") and the US Plan (the "US Plan") (collectively, the "Option Plans") which permit the granting of nonqualified share options to certain employees and directors. There were 1,501,165 Ordinary Shares available for issuance under the Option Plans, of which 383,371 Ordinary Shares were authorized for issuance under the US Plan.

On March 16, 2023, JATT's board of directors approved the Zura Bio Limited 2023 Equity Incentive Plan (the "Equity Incentive Plan") which became effective on the day immediately preceding the Closing Date of the Business Combination. The Equity Incentive Plan allows for the grant of share options, both incentive and nonqualified share options; SARs, stock appreciation rights ("SARs"), alone or in conjunction with other awards; restricted shares awards ("RSAs") and restricted share units ("RSUs"); incentive bonuses, which may be paid in cash, shares, or a combination thereof; and other share-based awards. On June 1, 2023, the Company's board of directors approved an increase to the number of Class A Ordinary Shares that may be issued under the Equity Incentive Plan by an additional 5,564,315 Class A Ordinary Shares. As of September 30, 2023 March 31, 2024, a maximum of 9,594,213 Class A Ordinary Shares may be issued under the Equity Incentive Plan.

The Class A Ordinary Shares issuable under the Equity Incentive Plan are subject to an annual increase on January 1st of each calendar year beginning on January 1, 2024, and ending on and including January 1, 2029, equal to the lesser of (i) 5.0% of the aggregate number of Class A Ordinary Shares outstanding

on the final day of the immediately preceding calendar year, (ii) 8,059,796 Class A Ordinary Shares or (iii) such smaller number of shares as is determined by the board. As of January 1, 2024, the Company's board of directors decided not to apply an increase to the Class A Ordinary Shares issuable under the Equity Incentive Plan.

On March 16, 2023, JATT's board of directors approved the Zura Bio Limited 2023 Employee Stock Purchase Plan (the "ESPP") which became effective on the day immediately preceding the Closing Date of the Business Combination. The maximum number of Class A Ordinary Shares that may be issued under the ESPP is 4,029,898, plus an aggregate number of Class A Ordinary Shares that are added under the Equity Incentive Plan on January 1st of each calendar year, beginning on January 1, 2024, and ending on and including January 1, 2029, as discussed above. The ESPP enables eligible employees of the Company and designated affiliates to purchase Class A Ordinary Shares at a discount of 15%. As of September 30, 2023 March 31, 2024, no shares have been issued under the ESPP.

Upon closing of the Business Combination, all equity awards of Legacy Zura that were issued and outstanding under the Option Plans were converted into comparable equity awards that are settled or exercisable for shares of the Company's Class A Ordinary Shares under the Equity Incentive Plan. As a result, each of Legacy Zura's equity awards were converted into an option to purchase Class A Ordinary Shares of the Company based on an exchange ratio of approximately 108.083.

Equity Incentive Plan

Share Options

The fair value of Equity Incentive Plan share options are estimated on the date of grant using the Black-Scholes option pricing model. The Company lacks significant company-specific historical and implied volatility information. Therefore, it estimates its expected share volatility based on the historical volatility of a publicly traded set of peer companies. Due to the lack of historical exercise history, the expected term of the Company's share options has been determined using the "simplified" method for awards. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is zero based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.

The following weighted-average assumptions were used to estimate the fair value of the 2023 Equity Incentive Plan share options issued during the three months ended March 31, 2024 and 2023:

	Three Months Ended	
	March 31,	
	2024	2023
Share price	\$ 3.53	\$ 8.16
Expected volatility	107.0 %	96.5 %
Risk-free rate	4.10 %	3.58 %
Expected life	6.0 years	6.1 years
Expected dividend yield	— %	— %

Table of Contents

equal to the expected term of the award. Expected dividend yield is zero based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future.

The following weighted-average assumptions were used to estimate the fair value of the Equity Incentive Plan share options issued during the three and nine months ended September 30, 2023 and the periods ended September 30, 2022:

For the Period from January 18,

	For the Three Months Ended		2022 (date of	
	September 30,		inception) to	
	2023	2022	For the Nine Months Ended September 30, 2023	September 30, 2022
Share price	\$ —	\$ —	\$ 6.26	\$ 0.77
Expected volatility	— %	— %	97.1 %	95.1 %
Risk-free rate	— %	— %	3.6 %	3.0 %
Expected life	—	—	6.1 years	5.9 years
Expected dividend yield	— %	— %	— %	— %

The following table summarizes the Company's share option activity for the **nine** months ended **September 30, 2023** **March 31, 2024**:

	Number of Options	Weighted Average Exercise Price (per share)	Weighted Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value (in thousands)	Number of Options	Weighted Average Exercise Price (per share)	Weighted Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value (in thousands)
Options outstanding at December 31, 2022	3,547	\$ 90.50	9.4	\$ 1,804				
Recapitalization	379,824	(89.66)	—	—				
Options outstanding at December 31, 2022	383,371	0.84	9.4	1,804				
Options outstanding at December 31, 2023					5,791,065	\$ 2.12	9.3	\$ 17,752
Granted	5,874,144	2.16	—	—	1,519,698	3.98	—	—
Forfeited	(576,044)	1.20	—	—	(202,575)	1.20	—	—
Options outstanding at September 30, 2023	5,681,471	\$ 2.17	9.5	\$ 25,626				
Options vested and exercisable at September 30, 2023	1,435,910	\$ 5.52	9.5	\$ 1,808				
Options outstanding at March 31, 2024					7,108,188	\$ 2.55	9.2	\$ 8,812
Options vested and exercisable at March 31, 2024					1,745,311	\$ 4.66	9.0	\$ 786

Included in the table above are **45,611** PSOs that vested upon the Company raising external capital of \$75 million or more. The milestone was considered **2,280,560** options to purchase Class A Ordinary Shares issued to certain directors, executives, and employees outside of the Company's control, and accordingly Equity Incentive Plan.

The weighted average grant date fair value of options granted during the vesting of the PSOs were not considered probable until the financing event occurs. During the **nine** months ended **September 30, 2023**, the **45,611** PSOs became vested **March 31, 2024** and an immaterial amount of share-based compensation expense **2023** was recognized in relation to these PSOs. **\$2.91** and **\$7.65**, respectively.

Market-Based Share Options

On March 20, 2023, the Company granted 306,373 options to purchase Class A Ordinary Shares ("Market-Based Share Options") to a certain Director of the Board. These awards will vest only to the extent that the 20-day volume weighted average trading price ("VWAP") of the Class A Ordinary Shares is over \$30 per Class A Ordinary Share at any time prior to the fifth anniversary of the grant date. These awards have an exercise price of \$8.16 and become exercisable when vested and the market condition is satisfied. These awards expire 10 years from the date of grant. The fair value of these Market-Based Share Options were estimated using a Monte Carlo valuation method.

[Table of Contents](#)

The following table sets forth the weighted-average assumptions used at the grant date to determine the fair value of the Company's **market-based** PSOs **Market-Based Share Options** granted during the **nine** months ended **September 30, 2023** **March 31, 2023**. No Market-Based Share Options were

granted during the three months ended **September 30, 2023** **March 31, 2024**:

	For the Nine Months Ended September 30, 2023	For the Three Months Ended March 31, 2023
Expected volatility	80.0 %	80.0 %
Risk-free rate	3.6 %	3.6 %
Expected life	2.2 years	2.2 years
Expected dividend yield	— %	— %
Fair value per Market-Based Share Options	\$ 4.66	\$ 4.66

The expense recognized related to Market-Based Share Options during the three **and nine** months ended **September 30, 2023** **March 31, 2024** and **2023** was **approximately** \$0.2 million and **\$0.4 million** **\$-0-**, respectively.

Restricted Share Units

The Company issued RSUs to certain employees, executives, and directors pursuant to the Equity Incentive Plan. The fair value has been estimated based on the closing price of the stock on the grant date.

	Number of RSUs	Weighted Average Grant Date Fair Value	Number of RSUs	Weighted Average Grant Date Fair Value
Unvested RSUs at December 31, 2022	—	\$ —		
Unvested RSUs at December 31, 2023			1,563,018	\$ 5.93
Granted	2,233,011	6.50	—	—
Vested	(20,000)	6.84		
Unvested RSUs at September 30, 2023	<u>2,213,011</u>	<u>\$ 6.50</u>		
Forfeited			(121,545)	5.24
Unvested RSUs at March 31, 2024			<u>1,441,473</u>	<u>\$ 5.95</u>

The expense recognized related to RSUs during the three and nine months ended **September 30, 2023** was **approximately** \$1.0 million and \$1.4 million, respectively.

Equity Award Modification

On April 7, 2023, the Company and its President and Chief Operating Officer (the "COO") entered into an agreement regarding the COO's departure from the Company (the "Severance Agreement"). In connection with Severance Agreement, 59,594 of the share options previously granted to the COO became fully vested and exercisable, with any shares purchased under the option subject to an 18-month lockup period. The Company recognized **approximately** \$0.6 million of incremental share-based compensation during the nine months ended **September 30, 2023** related to this share option modification.

Other Share-based Compensation

In accordance with the anti-dilution provisions of the Pfizer Agreement, Pfizer was issued additional Series A-1 convertible preferred shares upon the closing of the Business Combination that were immediately converted to 267,939 Class A Ordinary Shares. During the three and nine months ended **September 30, 2023**, the Company recognized expense in the amount of **\$-0-** and \$2.2 million, respectively, related to these Class A Ordinary Shares based on their grant-date fair value.

The expense recognized related to RSUs during the three months ended March 31, 2024 and 2023 was \$0.6 million and immaterial, respectively.

Restricted Share Awards

The Company converted RSU's granted to a certain director pursuant to the Equity Incentive Plan into RSAs during the year ended December 31, 2023. The fair value was estimated based on the closing price of the shares on the original grant date.

	Number of RSAs	Weighted Average Grant Date Fair Value
Unvested RSAs at December 31, 2023	499,993	\$ 8.16
Granted	—	—
Vested	(124,998)	8.16
Unvested RSAs at March 31, 2024	374,995	\$ 8.16

The expense recognized related to RSAs during the three months ended March 31, 2024 and 2023 was \$0.3 million and \$-0-, respectively.

Equity Award Modification

On January 10, 2024, the Company and its Chief Medical Officer (the "CMO") entered into an agreement regarding the CMO's departure from the Company (the "Severance Agreement"). In connection with the Severance Agreement, 67,525 of the share options previously granted to the CMO became fully vested and exercisable and 40,515 of the RSUs previously granted to the CMO became fully vested. All remaining share options and RSUs not vested were forfeited and cancelled. During the three months ended March 31, 2024, the Company recognized a reversal of approximately \$0.1 million of share-based compensation expense related to this modification.

Share-based Compensation Expense

Share-based compensation expense for all equity arrangements for the three months ended September 30, 2023 March 31, 2024, and 2022 and for the nine months ended September 30, 2023 and the period ended September 30, 2022 2023, was as follows:

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,	For the Period from January 18, 2022 (date of inception) to September 30,	For the Three Months Ended March 31,	For the Three Months Ended March 31,
	2023	2022	2023	2022	2024	2023
Research and development	\$ —	\$ —	\$ 2,186	\$ —	\$ 433	\$ 2,186
General and administrative	2,577	12	5,075	321	1,976	180
Total share-based compensation expense	\$ 2,577	\$ 12	\$ 7,261	\$ 321	\$ 2,409	\$ 2,366

As of September 30, 2023 March 31, 2024, there was approximately \$20.4 million \$20.5 million of total unrecognized share-based compensation expense related to options granted to employees, executives, and directors under the Company's equity plans that is expected to be recognized over a weighted average period of 1.8 3.1 years. As of September 30, 2023 March 31, 2024, there was approximately \$13.1 million \$6.6 million of total unrecognized share-based compensation expense related to RSUs granted to certain employees, executives, and directors under the Company's Equity Incentive Plan that is expected to be recognized over a weighted average period of 1.9 3.2 years. As of March 31, 2024, there was approximately \$3.0 million of total unrecognized share-based compensation expense related to RSAs granted to a certain director under the Company's Equity Incentive Plan that is expected to be recognized over a weighted average period of 3.0 years.

10. Note Payable

On December 8, 2022, the Company received \$7.6 million in net proceeds from the issuance of a promissory note (the "Note") issued to Hydra, LLC ("Hydra") with a face amount of \$8.0 million. The Note accrues interest at 9% per annum. The maturity date of the Note is the earlier of (i) twelve months from the date of the Note or (ii) five business dates after the date on which the Company consummates the Business Combination. The proceeds from the Note were used to acquire the 2022 Lilly License. If the registration statement on Form S-4 relating to the Business Combination had not been declared effective by the SEC by

February 15, 2023, or if the Business Combination was not consummated by March 31, 2023, Hydra had the right to accelerate the Note and receive an amount equal to 120% of the face amount of the Note, plus accrued interest. On March 8, 2023, the Company signed a limited waiver letter under the Note, pursuant to which Hydra agreed to waive its acceleration right in consideration of the Company paying to Hydra 125% of the principal amount (equal to \$10.0 million in the aggregate). The Note was repaid on March 20, 2023, upon the consummation of the Business Combination.

The Company elected to account for the Note at fair value (Note 4). The Company recorded any changes in the fair value of the Note during the period through other expense in the condensed consolidated statement of operations.

11.9. Commitments and Contingencies

Litigation

The Company is not a party to any material legal proceedings and is not aware of any pending or threatened claims. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities.

19

[Table of Contents](#)

12.10. Redeemable Noncontrolling Interest

As a finder's fee for the 2022 Lilly License, the Company's consolidated subsidiary Z33 issued 4,900,222 shares of Z33 Series Seed Preferred Shares to Stone Peach. Zura has the right, but not the obligation to purchase up to 50% of the Series Seed Preferred Shares issued to Stone Peach at a price per share of \$2.448869 for a period of two years from the date of the agreement. agreement (the "Call Option"). Stone Peach has the right, but not the obligation to sell up to 50% of the Series Seed Preferred Shares issued to Stone Peach to Zura for a price per share of \$2.040724 (the "Put Option"). Stone Peach may exercise its option at any time between the first anniversary and the second anniversary of the transaction. As it is not possible to specifically identify the shares that may be redeemed by exercising the Put Option, and the applicable unit of account is each share, the Company assessed that each share must be considered redeemable until the exercise or the expiration of the Put Option. Accordingly, the Z33 Series Seed Preferred Shares issued to Stone Peach represents redeemable noncontrolling interest.

25

[Table of Contents](#)

In April 2023, the Company agreed to, within six months of April 24, 2023, exercise its call option Call Option on 50% of the Z33 Series Seed Preferred Shares previously issued to Stone Peach. The Company agreed to settle its call option Call Option by issuing 2,000,000 Class A Ordinary Shares. The amended settlement terms represented an extinguishment and reissuance of the Z33 Series Seed Preferred Shares. The \$10.9 million difference between the estimated fair value of the new instrument issued and the carrying value of the Z33 Series Seed Preferred Shares was recorded as a deemed dividend to the redeemable noncontrolling interest and as an adjustment to net loss to arrive at net loss attributable to Class A ordinary shareholders on in the consolidated statement of operations.

In November 2023, the Company and Stone Peach amended the terms of the agreement, voiding the Company's obligation to exercise its Call Option, and instead reverting the Company's rights and obligations under the Call Option back to that of the original agreement. Stone Peach, in addition to the existing Put Option, was granted the right, but not the obligation to sell up to 50% of the Series Seed Preferred Shares issued to Stone Peach to Zura in exchange for 2,000,000 Class A Ordinary Shares (the "Put Right"). Stone Peach may exercise its Put Option and Put Right at any time between April 24, 2024, and April 24, 2028, under the new agreement. The amended settlement terms represented an extinguishment and reissuance of the Z33 Series Seed Preferred Shares. The \$9.2 million difference between the estimated fair value of the new instrument issued and the carrying value of the Z33 Series Seed Preferred Shares was recorded as a deemed contribution from the redeemable noncontrolling interest and as an adjustment to net loss to arrive at net loss attributable to Class A ordinary shareholders in the consolidated statement of operations. On March 31, 2024, the redeemable noncontrolling interest was remeasured from its redemption price to its initial carry amount, decreased for the noncontrolling interest's share of Z33's net loss, and the difference was recorded as an

adjustment to net loss to arrive at net loss attributable to Class A ordinary shareholders for the three months ended March 31, 2024 in the condensed consolidated statement of operations. The Company and Stone Peach are renegotiating the terms of the exercise of the call option.

As of September 30, 2023 March 31, 2024, and December 31, 2022 December 31, 2023, the redeemable noncontrolling interest balance was \$20.9 million \$11.7 million and \$10.0 million \$18.7 million, respectively.

13. 11. Subsequent Events

Lonza Milestone Payment April 2024 Private Placement

During October 2023, On April 18, 2024, the Company began drug substance manufacturing entered into subscription agreements (the "April 2024 Investor Agreements") with certain institutional and other accredited investors (the "Investors"), whereby the Company issued 18,732,301 Class A Ordinary Shares, par value \$0.0001 per share and pre-funded warrants (the "2024 Pre-Funded Warrants") to purchase up to 16,102,348 Class A Ordinary Shares. Each Class A Ordinary Share was sold at a third-party. As price of \$3.108 per Class A Ordinary Share and each 2024 Pre-Funded Warrant was sold at a result price of manufacturing \$3.107 per 2024 Pre-Funded Warrant for an aggregate purchase price of \$108.3 million. Each 2024 Pre-Funded Warrant has an exercise price of \$0.001 per Class A Ordinary Share and is exercisable for one Class A Ordinary Share at any time until exercised in full.

On April 18, 2024, the Company also entered into subscription agreements (the "April 2024 Insider Agreements" and together with a third-party other than Lonza, under the terms April 2024 Investor Agreements, the "April 2024 Private Placement") with certain officers, directors and affiliates of the Lonza License Company ("Insiders" and together with the first annual milestone payment Investors, the "2024 Subscribers"), whereby the Company issued 1,357,827 Class A Ordinary Shares, par value \$0.0001 per share sold a purchase price of \$0.4 million became due \$3.13 per Class A Ordinary Share for an aggregate purchase price of \$4.2 million.

The April 2024 Private Placement closed on April 22, 2024, from which the Company received total gross proceeds of approximately \$112.5 million, before deducting placement agent fees and payable, offering expenses payable by the Company.

26 20

[Table of Contents](#)

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis provides information that management believes is relevant to an assessment and understanding of our consolidated results of operations and financial condition. You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the our audited financial statements of Zura Bio Limited (referred to as "Legacy Zura" herein) as of December 31, 2022 December 31, 2023, included in the Current Report on Form 8-K 10-K filed with the SEC on April 6, 2023 March 28, 2024, and in conjunction with the unaudited condensed consolidated financial statements and notes thereto included elsewhere in this Quarterly Report on Form 10-Q.

In addition to historical information, this discussion and analysis contains forward-looking statements. These forward-looking statements are subject to risks and uncertainties, including those discussed in the section titled "Risk Factors" in our Registration Statement on Form S-4/A 10-K filed with the SEC on February 23, 2023 March 28, 2024, that could cause actual results to differ materially from historical results or anticipated results. Unless the context otherwise requires, references in this "Management's Discussion and Analysis of Financial Condition and Results of Operations" to "Zura," "we," "us," and "our" refer to Zura Bio Limited, a Cayman Islands exempted company formerly known as JATT Acquisition Corp., and its consolidated subsidiaries. References to JATT Acquisition Corp. or "JATT" refer to the Company prior to the consummation of the Business Combination.

Overview

Zura Bio Limited, formerly known as JATT Acquisition Corp., is a is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders. The experienced leadership team aims to become a leader in the autoimmunology autoimmune and inflammatory field.

We were incorporated as a Cayman Islands exempted company on March 10, 2021. Our wholly owned subsidiary, Zura Bio Limited ("Zura Bio UK") was formed in the United Kingdom, or UK, on January 18, 2022. Prior to March 20, 2023, our operations were conducted through Zura Bio UK.

We have a limited operating history. Since our inception, our operations have focused on organizing and staffing our company, business planning, raising capital and entering into collaboration agreements for conducting manufacturing, and research and development activities. Our lead product candidates are in the clinical testing stage, stage; however, we have not conducted any clinical tests ourselves, nor have any been conducted during the period since our inception. We do not have any product candidates approved for sale and have not generated any revenue from product sales. We have funded our operations up until March 31, 2024 through (i) the sale of equity, raising an aggregate of \$10.0 million of gross proceeds from the sale of shares of convertible preferred stock of Zura Bio UK through March 31, 2023; (ii) the issuance of a promissory note, receiving net proceeds of \$7.6 million in December 2022; (iii) proceeds from the Business Combination of \$56.7 million in March 2023; and (iv) the April 2023 Private Placement, raising an aggregate of \$80.0 million of gross proceeds from the sale of Class A Ordinary Shares and Pre-Funded Warrants during the nine months year ended September 30, 2023 December 31, 2023. In April 2024, we closed on a Private Placement, raising an aggregate of \$112.5 million of gross proceeds from the sale of Class A Ordinary Shares and Pre-Funded Warrants.

Since our inception, we have incurred significant operating losses. Our net loss for the three and nine months ended September 30, 2023 March 31, 2024, was \$8.3 million and \$51.9 million, respectively, \$7.7 million. As of September 30, 2023 March 31, 2024, we had an accumulated deficit of \$95.0 million \$111.2 million. We anticipate that our expenses will increase significantly in connection with our ongoing activities, as we:

- continue to advance the preclinical and clinical development of our product candidates and preclinical programs; candidates;
- conduct our planned preclinical studies and clinical and preclinical trials of ZB-168, ZB-106, and torudokimab, for our product candidates, as well as initiate and complete additional trials of future potential product candidates;
- seek regulatory approval for any product candidates that successfully complete clinical trials;
- scale up our clinical and regulatory capabilities;
- manufacture current good manufacturing practices, or cGMP, material for clinical trials or potential commercial sales;
- establish hire additional clinical, quality, regulatory, manufacturing, scientific and validate a commercial-scale cGMP manufacturing facility, or use a contract manufacturing organization; administrative personnel;
- establish a commercialization infrastructure and scale up manufacturing and distribution capabilities to commercialize any product candidates for which we may obtain regulatory approval;

27 21

[Table of Contents](#)

- adapt our regulatory compliance efforts to incorporate requirements applicable to marketed products;
- seek regulatory approval for any product candidates that successfully complete clinical trials;
- maintain, expand and protect our intellectual property portfolio;
- hire additional clinical, manufacturing quality control, regulatory, manufacturing and scientific and administrative personnel;
- add operational, financial, and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts; and
- incur additional legal, accounting, and other expenses in operating as a public company.

Business Combination

On March 20, 2023 (the "Closing Date"), we consummated the previously-announced transactions contemplated by the Business Combination Agreement, dated June 16, 2022, as amended on September 20, 2022, November 14, 2022, and January 13, 2023 by and among Zura Bio Limited, a limited company incorporated under the laws of England and Wales ("Zura Bio UK"), JATT Acquisition Corp, a Cayman Islands exempted company ("JATT"), JATT Merger Sub, a Cayman Islands exempted company and wholly owned subsidiary of JATT ("Merger Sub"), JATT Merger Sub 2, a Cayman Islands exempted company and wholly owned subsidiary of JATT ("Merger Sub 2") and Zura Bio Holdings Ltd, a Cayman Islands exempted company ("Holdco"), following the approval at an extraordinary general meeting of JATT's shareholders held on March 16, 2023.

Pursuant to the Business Combination Agreement, (a) before the closing of the Business Combination, Holdco was established as our new holding company and became a party to the Business Combination Agreement; and (b) on the closing date, in sequential order: (i) Merger Sub merged with and into

Holdco, with Holdco continuing as the surviving company and a wholly owned subsidiary of JATT (the "Merger"); (ii) immediately following the Merger, Holdco merged with and into Merger Sub 2, with Merger Sub 2 continuing as the surviving company and a wholly owned subsidiary of JATT (the "Subsequent Merger"); and (iii) JATT changed its name to "Zura Bio Limited" ("Zura Bio").

Subject to, and in accordance with, the terms and conditions of the Business Combination Agreement, at the Closing, (i) each JATT unit was (to the extent not already separated) automatically separated and the holder thereof was deemed to hold one JATT Class A Ordinary Share and one-half of a JATT warrant; (ii) in consideration for the Merger, JATT issued to holders of Holdco's issued and outstanding shares immediately prior to the Effective Time (as defined in the Business Combination Agreement) an aggregate of 14,558,067 JATT Class A Ordinary Shares (including 499,993 JATT Class A Ordinary Shares underlying restricted share units granted to Amit Munshi, the Company's Non-Executive Chairman) plus 1,941,933 options to acquire JATT Class A Ordinary Shares for which outstanding options to acquire Holdco Class A Ordinary Shares were exchanged on Closing; and (iii) pursuant to the terms and conditions of JATT's existing amended and restated memorandum and articles of association, all then-outstanding Class B Class A Ordinary Shares, par value \$0.0001 per share, were automatically converted into JATT Class A Ordinary Shares on a one-for-one basis.

On the Closing Date, Ewon Comfortech Co., Ltd. ("Ewon"), an institutional accredited investor which is an indirect investor in Zura through its equity interest in Hana Immunotherapeutics LLC ("Hana"), purchased from JATT 2,000,000 JATT Class A Ordinary Shares and Eugene Investment & Securities Co., Ltd ("Eugene"), an unaffiliated institutional credited investor, purchased from JATT 9,950 JATT Class A Ordinary Shares (Ewon, together with Eugene, the "PIPE Investors"), for an aggregate of 2,009,950 JATT Class A Ordinary Shares (the "PIPE Shares") at a price of \$10.00 per share, for an aggregate purchase price of \$20,099,500 (the "PIPE Financing"), pursuant to the subscription agreement entered into by JATT and the Ewon as of June 16, 2022, as amended on November 25, 2022 (the "Ewon PIPE Subscription Agreement") and the subscription agreement entered into by JATT and Eugene as of March 13, 2023 (the "Eugene PIPE Subscription Agreement" and, together with the Ewon PIPE Subscription Agreement, the "PIPE Subscription Agreements").

[Table of Contents](#)

At the Closing of the Business Combination, Athanor Master Fund, LP and Athanor International Master Fund, LP (collectively, the "FPA Investors"), each of which is an unaffiliated institutional investor, purchased (i) an aggregate of 3,000,000 JATT Class A Ordinary Shares at \$10 per share for \$30,000,000; (ii) an aggregate of 1,301,633 JATT Class A Ordinary Shares at \$10 per share for \$13,016,330 (the "Redemption Backstop") as public share redemptions were greater than 90% at the time of the Business Combination (the "Excess Redemptions"); and (iii) an additional 2,500,000 JATT Class A Ordinary Shares in consideration for the FPA Investors entering into the latest amendment, but for no additional monetary consideration, to the forward purchase agreements JATT and the FPA Investors entered into on August 5, 2021, as amended and restated on January 27, 2022 and as amended on March 8, 2023 (the "Forward Purchase Agreement").

The Business Combination together with the PIPE financing, the Forward Purchase Agreement, and the Redemption Backstop, generated approximately \$56.7 million in net proceeds. On March 21, 2023, the Company's Class A Ordinary Shares and public warrants began trading on the Nasdaq under the symbols "ZURA" and "ZURAW," respectively.

April 2024 Private Placement

On April 18, 2024, we entered into subscription agreements (the "April 2024 Investor Agreements") with certain institutional and other accredited investors (the "Investors"), whereby the Company issued 18,732,301 Class A Ordinary Shares, par value \$0.0001 per share and pre-funded warrants (the "2024 Pre-Funded Warrants") to purchase up to 16,102,348 Class A Ordinary Shares. Each Class A Ordinary Share was sold at a price of \$3.108 per Class A Ordinary Share and each 2024 Pre-Funded Warrant was sold at a price of \$3.107 per 2024 Pre-Funded Warrant for an aggregate purchase price of \$108.3 million.

On April 18, 2024, we also entered into subscription agreements (the "April 2024 Insider Agreements" and together with the April 2024 Investor Agreements, the "April 2024 Private Placement") with certain officers, directors and affiliates of the Company ("Insiders" and together with the Investors, the "2024 Subscribers"), whereby the Company issued 1,357,827 Class A Ordinary Shares, par value \$0.0001 per share sold a purchase price of \$3.13 per Class A Ordinary Share for an aggregate purchase price of \$4.2 million.

The April 2024 Private Placement closed on April 22, 2024 from which we received gross proceeds of approximately \$112.5 million.

April 2023 Private Placement

On April 26, 2023, the Company entered into its second PIPE subscription agreement (the "April 2023 Private Placement") with certain accredited investors (the "Subscribers"), whereby the Company issued 15,041,530 Class A Ordinary Shares, par value \$0.0001 per share and pre-funded warrants (the "Pre-

Funded "2023 Pre-Funded Warrants") to purchase up to 3,782,000 Class A Ordinary Shares. Each Class A Ordinary Share was sold at a price of \$4.25 per Class A Ordinary Share and each Pre-Funded Warrant was sold at a price of \$4.249 per Pre-Funded Warrant for an aggregate purchase price of \$80.0 million.

Concurrently with the April 2023 Private Placement, the Company agreed to, within six months of April 24, 2023, exercise its call option on 50% of the Z33 Series Seed Preferred Shares previously issued to Stone Peach. The Company agreed to settle its call option by issuing 2,000,000 Class A Ordinary Shares. The amended settlement terms represented an extinguishment and reissuance of the Z33 Series Seed Preferred Shares. The \$10.9 million difference between the estimated fair value of the new instrument issued and the carrying value of the Z33 Series Seed Preferred Shares was recorded as a deemed dividend to the redeemable noncontrolling interest. The Company and Stone Peach are renegotiating the terms of the exercise of the call option.

2023 Lilly License

On April 26, 2023, the Company's newly-formed newly formed subsidiary ZB17 LLC ("ZB17") entered into a license agreement (the "2023 Lilly License" and, together with the 2022 Lilly License, the "Lilly Licenses") with Lilly, for an exclusive license to develop, manufacture and commercialize a certain bispecific antibody relating to IL-17 and BAFF ("ZB-106") in exchange for an upfront payment consisting of \$5.8 million as well as 1,000,000 Class A Ordinary Shares issued at a fair value of \$7.84 per Class A Ordinary Share. In addition, ZB17 will make made a payment of \$5.0 million upon to Lilly during the three months ended March 31, 2024, in connection with the receipt of certain know-how, data, information and materials that Lilly is was required to provide under the license agreement.

22

[Table of Contents](#)

As a finder's fee for arranging the acquisition of the 2023 Lilly License, ZB17 granted to Stone Peach the right, but not the obligation, to purchase 4.99% of the fully diluted equity of ZB17 for \$1.0 million (the "Stone Peach Call Right"). The Stone Peach Call Right is not exercisable until after the last patient is dosed in any single next clinical trial with ZB-106 and expires one year from the date of first indication approval for ZB-106 by the FDA or the EMA, European Medicines Agency ("EMA"). The Stone Peach Call Right represents noncontrolling interest in the Company's subsidiary, ZB17.

As additional consideration, Stone Peach will receive receives annual payments first of \$0.6 million, and increasing by 10% annually, so long as the Company maintains its license for ZB-106 and beginning on May 1, 2023. May 1st of each year. We will account for these annual payments as they become due.

As a finder's fee for arranging the acquisition of the 2023 Lilly License, the Company we agreed to make a one-time milestone payment of \$5.0 million to BAFFX17, Ltd ("BAFFX17") upon the occurrence of either: (i) a change of control transaction, (ii) the closing of an issuance of equity or equity-linked securities by the Company of at least \$100.0 million (iii) the consummation of a sale of assets resulting in net proceeds in excess of \$100.0 million, or (iv) the Company's fully diluted shares outstanding exceed 52,500,000 shares (on a split adjusted basis).

29

[Table](#) As the Company's fully diluted shares outstanding exceeded 52,500,000 shares prior to December 31, 2023, the \$5.0 million fee was recorded in accounts payable and accrued expenses in the condensed consolidated balance sheet as of Contents March 31, 2024 and became due as of April 24, 2024.

In addition to the consideration transferred during the nine months ended September 30, 2023, the The Company is obligated to make 4 development milestone payments to Lilly up to an aggregate of \$155.0 million, and sales milestone payments up to an aggregate of \$440 million based on respective thresholds of net sales of products developed from ZB-106. The Company is also obligated to pay Lilly over a multi-year period (twelve years, or upon the later expiration of regulatory exclusivity of ZB-106 in a country) an annual earned royalty at a marginal royalty rate in the mid-single digits to low-double digits, with increasing rates depending on net sales in the respective calendar year, based on a percentage of sales within varying thresholds for a certain period of years. The Company is also obligated to pay BAFFX17 a fee equal to 3% of any milestone or royalty payments due to Lilly pursuant to the terms of either the 2022 Lilly License and the 2023 Lilly License with Lilly. Upon receiving written approval from the FDA, EMA, or similar regulatory authority of the Investigational New Drug ("IND") and commencement and the commencement of a clinical trial in the applicable jurisdiction for ZB-106, Stone Peach will also receive a one-time payment of \$4.5 million. Stone Peach will also receive a one-time milestone payment of \$25 million upon either (i) certain equity-related transactions, or (ii) the

receipt of regulatory approval from the applicable regulatory authority for any new indication in the applicable jurisdiction. Furthermore, Stone Peach was granted a royalty of 2% of the aggregate net sales of any products developed from the Compound. As of March 31, 2024, none of the contingent payments were due.

Appointment 2022 Lilly License

On December 8, 2022, the Company's consolidated subsidiary, Z33 Bio Inc. ("Z33"), entered into a license agreement (the "2022 Lilly License") with Lilly pursuant to which Lilly granted Z33 an exclusive (even as to Lilly), royalty-bearing global license to develop, manufacture, and commercialize certain intellectual property owned by Lilly relating to its IL-33 compound.

As a finder's fee in connection with arranging the acquisition, Z33 issued to Stone Peach Properties, LLC ("Stone Peach") 4,900,222 shares of Z33 Series Seed Preferred Shares, which was included in the measurement of the cost of the acquired asset. As of March 31, 2024, we have the right, but not the obligation to purchase up to 50% of the Series Seed Preferred Shares issued to Stone Peach at a price per share of \$2.448869 for a period of two years from the date of the agreement (the "Call Option"). Stone Peach has the right, but not the obligation to sell up to 50% of the Series Seed Preferred Shares issued to Stone Peach to Zura for a price per share of \$2.040724 (the "Put Option"). Stone Peach also has the right, but not the obligation to sell up to 50% of the Series Seed Preferred Shares issued to Stone Peach to Zura in exchange for 2,000,000 Class A Ordinary Shares (the "Put Right"). Stone Peach may exercise its Put Option and Put Right at any time between April 24, 2024 and April 24, 2028. The Z33 Series Seed Preferred Shares represent redeemable noncontrolling interest in our subsidiary, Z33.

The Company is obligated to pay \$3.0 million to Lilly under the 2022 Lilly License upon the completion of a Director financing by the Company with gross proceeds exceeding \$100 million, in cash or in services, paid to Z33. If the \$3.0 million milestone payment is not made by December 7, 2025, Lilly may terminate the 2022 Lilly License and reclaim the asset. The Company is further obligated to make 10 commercial, development and regulatory milestone payments up to an aggregate of \$155.0 million and sales milestone payments up to an aggregate of \$440.0 million based on respective thresholds of net sales of products developed from the licensed compound. The Company will also pay an annual earned royalty to Lilly at a marginal royalty rate between in the mid-single to low-double digits (less than 20%), with increasing rates based on net sales in the respective calendar year, based on a percentage of sales

[Table of Contents](#)

within varying thresholds for a certain period of the year. The Company will account for these contingent payments when they become due. As of March 31, 2024, none of the contingent payments were due.

Pfizer Agreement

On May 31, 2023 March 22, 2022, the Company entered into a license agreement and a Series A-1 Subscription and Shareholder's Agreement (collectively, the "Pfizer Agreement") with Pfizer. The Company is obligated to make 11 future development and regulatory milestone payments aggregating up to \$70.0 million and sales milestone payments up to an aggregate of \$525.0 million based on respective thresholds of net sales of products (developed from the licensed compound) (the "Products"). The Company will also pay an annual earned royalty at a marginal royalty rate in the mid-single digits to low double digits (less than 20%), based on thresholds of net sales of Products. Royalties are payable on a country-by-country basis for a certain period of years or upon the later expiration of regulatory exclusivity of the Company's Products in a country.

The Company is also subject to a potential multi-million dollar transaction payment if, within a certain period the Company has (a) certain changes in control, excluding an initial public offering or any business combination where the securities of the Company are listed on a stock exchange (e.g., a transaction with a special purpose acquisition company), or (b) the Company sublicenses or divests of its rights to the Products.

The Company does not owe any other amounts under the Pfizer Agreement as of March 31, 2024.

Chief Executive Officer Transition

On March 24, 2024, the Board of Directors (the "Board") of the Company increased the size of approved a CEO transition from Someit Sidhu, our Founder, Chief Executive Officer and Director, to Robert Lisicki, effective April 8, 2024. Dr. Sidhu remains on the Board from seven directors to nine directors. On June 22, 2023, as a non-independent Director and Mr. Lisicki joined the Board appointed Parvinder Thiara to fill the vacancy on and serve as a member of the Board, to serve until the next annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier death, resignation or removal. Mr. Thiara has no family relationships with any of the executive officers or directors of the Company. There have been no transactions in the past two years to

which the Company or any of its subsidiaries was or is to be a party, in which Mr. Thiara had, or will have, a direct or indirect material interest. **non-independent Director.**

Components of Operating Results

Operating Expenses

General and Administrative Expenses

General and administrative ("G&A") expenses primarily consist of professional fees for legal, accounting, and consulting costs relating to corporate matters, as well as salaries and related costs for personnel in executive and administrative functions, including share-based compensation.

We anticipate that our general and administrative expenses will increase in the future as we continue to support research and development activities and incur increased costs of operating as a public company. These costs include increased headcount to support expanded operations and infrastructure.

Additionally, we anticipate increased costs associated with maintaining compliance with Nasdaq rules and SEC requirements such as accounting, audit, legal and consulting services, as well as director and officer liability insurance, investor and public relations activities.

Research and Development Expenses

Research and development ("R&D") expenses consist primarily of all direct and indirect operating expenses supporting the processes in development, including consulting fees for medical and manufacturing advisory services, and costs related to manufacturing material for preclinical studies, clinical studies, payroll and benefits, which includes share-based compensation, for research and development employees, licensing fees, and study acquisition costs. Expenses are recognized as the related goods are delivered or the services are performed.

R&D expenses include the cost of in-process research and development ("IPR&D") assets purchased in an asset acquisition transaction. IPR&D assets are expensed unless the assets acquired are deemed to have an alternative future use, provided that the acquired asset did not also include processes or activities that would constitute a "business" as defined under U.S. GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. Acquired IPR&D payments are immediately expensed in the period in which they are incurred and include upfront payments, as well as transaction

24

[Table of Contents](#)

fees and subsequent pre-commercial milestone payments. Research and development costs incurred after the acquisition are expensed as incurred. R&D expenses also include the remeasurement of the research and development license consideration liability.

30

Table. The research and development license consideration liability represented an obligation to issue either preferred shares of Contents the Company's subsidiary or Class A Ordinary Shares to Lilly as consideration for the 2022 Lilly License, which was ultimately settled through the issuance of Class A Ordinary Shares upon the closing of the Business Combination.

Research and development expenses could include:

- employee-related expenses, including salaries, bonuses, benefits, share-based compensation and other related costs for those employees involved in research and development efforts;
- external research and development expenses incurred under agreements with clinical research organizations, investigative sites and consultants to conduct our preclinical studies;
- costs related to manufacturing material for preclinical studies and clinical trials, including fees paid to contract manufacturing organizations;

- laboratory supplies and research materials;
- costs related to compliance with regulatory requirements; and
- facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent, maintenance of facilities, insurance and equipment.

Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We plan to substantially increase our research and development expenses for the foreseeable future as we develop our product candidates and manufacturing processes and conduct discovery and research activities for our **preclinical and** clinical programs. We cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future **preclinical clinical studies and clinical trials** of our product candidates due to the inherently unpredictable nature of **preclinical and** clinical development. Clinical **and preclinical** development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to how we pursue our product candidates and how much funding to direct to each program on an ongoing basis in response to the results of future **preclinical studies and** clinical trials, regulatory developments and our ongoing assessments as to commercial potential. We will need to raise substantial additional capital in the future. Our clinical development costs are expected to increase as we commence, continue and expand our clinical trials. Our future expenses may vary significantly each period based on factors such as:

- expenses incurred to conduct preclinical studies required to advance our product candidates into clinical trials;
- per patient clinical trial costs, including based on the number of doses that patients receive;
- the number of patients who enroll in each clinical trial;
- the number of clinical trials required for approval;
- the number of sites included in the clinical trials;
- the countries in which the clinical trials are conducted;
- the length of time required to enroll eligible patients;
- the drop-out or discontinuation rates of patients;
- potential additional safety monitoring requested by regulatory agencies;
- the duration of patient participation in clinical trials and follow-up;

25

[Table of Contents](#)

- the phase of development of the product candidate;
- third party contractors failing to comply with regulatory requirements or meet their contractual obligations in a timely manner, or at all;

31

[Table of Contents](#)

- the cost of insurance, including product liability insurance, in connection with clinical trials;
- regulators or institutional review boards requiring that we or our investigators suspend or terminate clinical development for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks; and
- the efficacy and safety profile of our product **candidates candidates**.

Results of Operations

Comparison of the Three Months Ended September 30, 2023, March 31, 2024, and 2022 2023

The following table summarize our results of operations for the periods presented (in thousands):

	For the Three Months Ended			
	September 30,		\$	%
	2023	2022	Change	Change
Operating expenses:				
Research and development	\$ 3,965	\$ 415	\$ 3,550	*
General and administrative	6,222	653	5,569	*
Total operating expenses	10,187	1,068	9,119	*
Loss from operations	(10,187)	(1,068)	(9,119)	*
Other expense/(income), net:				
Other expense, net	4	34	(30)	(88)%
Interest income	(815)	—	(815)	100 %
Dividend income	(987)	—	(987)	100 %
Change in fair value of private placement warrants	(119)	—	(119)	100 %
Total other expense/(income), net	(1,917)	34	(1,951)	*
Loss before income taxes	(8,270)	(1,102)	(7,168)	*
Income tax benefit	—	—	—	*
Net loss before redeemable noncontrolling interest	(8,270)	(1,102)	(7,168)	*
Net loss attributable to redeemable noncontrolling interest	—	—	—	*
Net loss	(8,270)	(1,102)	(7,168)	*
Deemed dividend to redeemable noncontrolling interest	—	—	—	*
Net loss attributable to Ordinary Shareholders of Zura	\$ (8,270)	\$ (1,102)	\$ (7,168)	*

	For the Three Months Ended	For the Three Months Ended		
	March 31,	March 31,	\$	%
	2024	2023	Change	Change
Operating expenses:				
Research and development	\$ 3,593	\$ 4,884	\$ (1,291)	(26)%
General and administrative	4,786	2,835	1,951	69 %
Total operating expenses	8,379	7,719	660	9 %
Loss from operations	(8,379)	(7,719)	(660)	9 %
Other (income)/expense, net:				
Other (income)/expense	(23)	10	(33)	(330)%
Interest income	(1,215)	(1)	(1,214)	* %
Change in fair value of private placement warrants	606	(177)	783	442 %
Change in fair value of note payable	—	2,244	(2,244)	(100)%
Total other (income)/expense, net	(632)	2,076	(2,708)	(130)%
Loss before income taxes	(7,747)	(9,795)	2,048	(21)%
Income tax benefit	—	—	—	— %
Net loss before redeemable noncontrolling interest	(7,747)	(9,795)	2,048	(21)%
Net loss attributable to redeemable noncontrolling interest	—	203	(203)	(100)%
Net loss	(7,747)	(9,592)	1,845	(19)%
Accretion of redeemable noncontrolling interest to redemption value	—	(203)	203	(100)%
Adjustment of redeemable noncontrolling interest from redemption value to carrying value	7,017	—	7,017	100 %

Net loss attributable to Ordinary Shareholders of				
Zura	\$	(730)	\$	(9,795)
			\$	9,065
				(93)%

*Percentage change not meaningful

[Table of Contents](#)

Operating Expenses

Research and Development Expenses (in thousands):

	For the Three Months Ended March 31, 2024	For the Three Months Ended March 31, 2023	\$ Change	% Change
Research and development	\$ 3,593	\$ 4,884	\$ (1,291)	(26)%

Research and development expenses increased decreased by \$3.6 million \$1.3 million for the three months ended September 30, 2023 March 31, 2024 compared to the three months ended September 30, 2022 March 31, 2023. This was primarily due to a decrease of \$2.2 million related to the issuance of additional shares to Pfizer under an anti-dilution provision during the three months ended March 31, 2023. The increase decrease was also due to \$3.1 million \$1.9 million related to the change in fair value of increased costs our research and development license consideration liability during the three months ended March 31, 2023. The decrease was partially offset by an increase of \$1.4 million in expenses related to manufacture products compensation for use personnel in clinical studies research and development functions including share-based compensation and an increase of \$0.5 million in \$1.4 million of costs incurred for clinical consulting services and regulatory consulting services. manufacturing of our product candidates.

General and Administrative Expenses (in thousands):

	For the Three Months Ended March 31, 2024	For the Three Months Ended March 31, 2023	\$ Change	% Change
General and administrative	\$ 4,786	\$ 2,835	\$ 1,951	69 %

General and administrative expenses increased by \$5.6 million \$2.0 million for the three months ended September 30, 2023 March 31, 2024 compared to the three months ended September 30, 2022 March 31, 2023. The increase was primarily due to increases of \$4.2 million \$1.6 million in expenses related compensation for personnel in executive and administrative functions including share-based compensation, as well as an increase of \$0.7 million \$0.2 million in

[Table of Contents](#)

professional fees for legal and accounting costs incurred related to our ongoing operations as a public company, and an increase of \$0.7 million \$0.2 million of travel and office expenses.

Other (Income) Expense, (Income) Net

Other expense, net (Income) Expense

Other (income)/expense decreased changed by an immaterial a nominal amount for the three months ended September 30, 2023 March 31, 2024 compared to the three months ended September 30, 2022 March 31, 2023. This decrease change was primarily due to a decrease in foreign exchange transaction loss, gain for the three months ended March 31, 2024 as compared to a foreign exchange transaction loss for the three months ended March 31, 2023.

Interest income

Interest income increased by \$0.8 million \$1.2 million for the three months ended September 30, 2023 March 31, 2024 as compared to the three months ended September 30, 2022 March 31, 2023. This increase is due to an increase in our cash and cash equivalents balance during the three months ended September 30, 2023 March 31, 2024 as compared to the three months ended September 30, 2022.

Dividend income

Dividend income increased by \$1.0 million for the three months ended September 30, 2023 compared to the three months ended September 30, 2022. The Company held no dividend-generating cash equivalents during the three months ended September 30, 2022.

Change in fair value of private placement warrants

Revaluation gain on the liability-classified private placement warrants assumed in the Business Combination was \$0.1 million for the three months ended September 30, 2023. No warrants were outstanding during the three months ended September 30, 2022.

Net loss attributable to redeemable noncontrolling interest

Net loss attributable to redeemable noncontrolling interest was \$-0- for the three months ended September 30, 2023, representing the noncontrolling shareholder's interest in the net loss of our consolidated subsidiary. The redeemable noncontrolling interest was not outstanding during the three months ended September 30, 2022.

Deemed Dividend to Redeemable Noncontrolling Interest

Deemed dividend to the redeemable noncontrolling interest was \$-0- for the three months ended September 30, 2023. The redeemable noncontrolling interest was not outstanding during the three months ended September 30, 2022.

[Table of Contents](#)

Comparison of the Nine Months Ended September 30, 2023 and the Period from January 18, 2022 (date of inception) to September 30, 2022

The following table summarize our results of operations for the periods presented (in thousands):

	For the Nine Months Ended September 30, 2023	For the Period from January 18, 2022 (date of inception) to September 30, 2022	\$ Change	% Change
Operating expenses:				
Research and development	\$ 37,079	\$ 8,000	\$ 29,079	*
General and administrative	14,732	1,814	12,918	*
Total operating expenses	51,811	9,814	41,997	*
Loss from operations	(51,811)	(9,814)	(41,997)	*
Other expense/(income), net:				
Other expense, net	7	32	(25)	(78)%
Interest income	(816)	—	(816)	100 %
Dividend income	(1,392)	—	(1,392)	100 %
Change in fair value of private placement warrants	236	—	236	100 %
Change in fair value of note payable	2,244	—	2,244	100 %

Total other expense/(income), net	279	32	247	*
Loss before income taxes	(52,090)	(9,846)	(42,244)	*
Income tax benefit	—	—	—	*
Net loss before redeemable noncontrolling interest	(52,090)	(9,846)	(42,244)	*
Net loss attributable to redeemable noncontrolling interest				
interest	203	—	203	100 %
Net loss	(51,887)	(9,846)	(42,041)	*
Accretion of redeemable noncontrolling interest to redemption value	(203)	—	(203)	100 %
Deemed dividend to redeemable noncontrolling interest	(10,875)	—	(10,875)	100 %
Net loss attributable to Ordinary Shareholders of Zura	\$ (62,965)	\$ (9,846)	\$ (53,119)	*

*Percentage change not meaningful

Operating Expenses

Research and Development Expenses

Research and development expenses increased by \$29.1 million for the nine months ended September 30, 2023 compared to the period ended September 30, 2022. This was primarily due to an increase of \$19.7 million of costs incurred to acquire licenses, as we recognized \$7.5 million of expense related to the acquisition of an in-process research and development ("IPR&D") license from Pfizer during the period months ended September 30, 2022 and \$27.2 million in license and milestone fees related to the acquisition of an IPR&D license from Lilly during the nine months ended September 30, 2023. The increase was also due to the issuance of additional shares to Pfizer under an anti-dilution provision of \$2.2 million recognized during the nine months ended September 30, 2023, an increase of \$1.9 million related to the change in fair value of our research and development license consideration liability, and an increase of \$4.3 million of costs to manufacture products for use in clinical studies, and an increase of \$1.0 million of clinical and regulatory consulting services.

General and Administrative Expenses

General and administrative expenses increased by \$12.9 million for the nine months ended September 30, 2023 compared to the period ended September 30, 2022. The increase was primarily due to increases of \$9.3 million in expenses related compensation for personnel in executive and administrative functions including share-based compensation, as well as an increase of \$2.2 million in

Table of Contents

professional fees for legal and accounting costs incurred related to our ongoing operations as a public company, an increase of \$1.4 million of travel and office expenses.

Other Expense (Income)

Other expense, net

Other expense decreased by an immaterial amount for the three months ended September 30, 2023 compared to the three months ended September 30, 2022. This decrease was primarily due to a decrease in foreign exchange transaction loss.

Interest income

Interest income increased by \$0.8 million for the nine months ended September 30, 2023 compared to the period ended September 30, 2022. This increase is due to an increase in our cash balance during the nine months ended September 30, 2023 compared to the period ended September 30, 2022.

Dividend income

Dividend income increased by \$1.4 million for the nine months ended September 30, 2023 compared to the period ended September 30, 2022. The Company held no dividend-generating cash equivalents during the period ended September 30, 2022 March 31, 2023.

Change in fair value of private placement warrants

Revaluation loss on the liability-classified private placement warrants assumed in the Business Combination was \$0.6 million during the three months ended March 31, 2024 compared to a revaluation gain of \$0.2 million for the nine three months ended September 30, 2023. No warrants were outstanding during the period ended September 30, 2022 March 31, 2023.

Change in fair value of note payable

Revaluation loss on the note payable was \$2.2 million for the nine three months ended September 30, 2023 March 31, 2023, as the note was remeasured to its settlement value. The note payable was not outstanding during value and settled at the period ended September 30, 2022, closing of the Business Combination.

[Table of Contents](#)

Net loss attributable to redeemable noncontrolling interest

Net loss attributable to redeemable noncontrolling interest was \$0.2 million for the nine three months ended September 30, 2023 March 31, 2023, representing the noncontrolling shareholder's interest in the net loss of our consolidated subsidiary, Z33. The redeemable noncontrolling interest was not outstanding during Z33 had an immaterial amount of net loss for the period three months ended September 30, 2022 March 31, 2024.

Accretion Adjustment of redeemable noncontrolling interest to redemption value

Accretion of redeemable noncontrolling interest to redemption value was \$0.2 million for the nine three months ended September 30, 2023 March 31, 2023. The For the three months ended March 31, 2024, redeemable noncontrolling interest was not outstanding during the period ended September 30, 2022.

Deemed Dividend adjusted from its redemption value to Redeemable Noncontrolling Interest

Deemed dividend to the redeemable noncontrolling interest was \$10.9 million its initial fair value, decreased for the nine months ended September 30, 2023, due to noncontrolling shareholder's interest in net loss of Z33. This \$7.0 million adjustment was the modification result of a decrease in the terms redemption price below the initial fair value, less the noncontrolling shareholder's interest in net loss of the Z33 Series Seed Preferred Shares issued to Stone Peach. The redeemable noncontrolling interest was not outstanding during the period ended September 30, 2022 as of March 31, 2024.

Liquidity and Capital Resources

Overview

Since our inception, we have not generated any revenue and expect to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of September 30, 2023 March 31, 2024, we had cash and cash equivalents of \$103.9 million \$89.8 million. As of September 30, 2023 March 31, 2024, we have funded our operations through (i) the sale of equity, raising an aggregate of \$10.0 million of gross proceeds from the sale of our convertible preferred shares; (ii) the issuance of a promissory note, receiving net proceeds of \$7.6 million;

[Table of Contents](#)

(iii) proceeds from the Business Combination of \$56.7 million in March 2023; and (iv) the April 2023 Private Placement, raising an aggregate of \$80.0 million of gross proceeds from the sale of Class A Ordinary Shares and Pre-Funded Warrants pre-funded warrants in May and June 2023. In April 2024, we closed the

April 2024 Private Placement, raising an additional \$112.5 million of gross proceeds from the sale of Class A Ordinary Shares and pre-funded warrants.

We have experienced operating losses and cash outflows from operations since inception and will require ongoing financing in order to continue our research and development activities. We have not earned any revenue or reached successful commercialization of our products. Our future operations are dependent upon our ability to finance our cash requirements which will allow us to continue our research and development activities and the commercialization of our products. There can be no assurance that we will be successful in continuing to finance our operations.

Capital Requirements

To date, we have not generated revenue from any source, including the commercial sale of approved drug products, and we do not expect to generate revenue for at least the next few years. If we fail to complete the development of our product candidates in a timely manner or fail to obtain their regulatory approval, our ability to generate future revenue will be adversely affected. We do not know when, or if, we will generate any revenue from our product candidates, and we do not expect to generate revenue unless and until we obtain regulatory approval of, and commercialize, our product candidates.

We expect our expenses to continue to increase significantly in connection with our ongoing activities, particularly as we continue the research and development, and seek marketing approval for our product candidates, as well as administrative costs associated with supporting our operations. In addition, if we obtain approval for any of our product candidates, we expect to incur significant commercialization expenses related to sales, marketing, manufacturing and distribution. Furthermore, we expect to incur additional costs associated with operating as a public company.

We will also be responsible to Pfizer and Lilly for significant future contingent payments under the Pfizer Agreement, the 2022 Lilly License, and the 2023 Lilly License (collectively with the 2022 Lilly License, the "Lilly Licenses") upon the achievement of certain development, regulatory, and sales milestones, as well as ongoing royalties on net commercial sales. The size and timing of these milestone payments will vary greatly depending upon a number of factors, and it is therefore difficult to estimate the total payments that could become payable to Pfizer and Lilly and when those payments would be due. If we achieve all of the milestones, we would be obligated to pay multimillion dollar development and regulatory milestone payments and sales milestone payments. We will be required to pay certain of these milestone payments prior to the time at which we are able to generate sufficient revenue, if any, from commercial sales of any of our product candidates. We intend to fund these milestone payments using a portion of the proceeds from the Business Combination, the April 2023 Private Placement, and the April 2023 2024 Private Placement. In addition to milestone payments, we are also

[Table of Contents](#)

required to pay Pfizer and Lilly under the Pfizer Agreement and Lilly Licenses, respectively, ongoing royalties in the mid-single digits to low double-digits (less than 20%) percentage range based upon thresholds of net sales of products.

We anticipate that we will need substantial additional funding in connection with our continuing operations. We intend to devote most of the net proceeds from the Business Combination, the April 2023 Private Placement, and the April 2023 2024 Private Placement to the preclinical and clinical development of our product candidates, our public company compliance costs and certain milestone payments under the Pfizer Agreement and Lilly Licenses. Based on our current business plans, we believe that the net proceeds from the Business Combination and the Private Placement (as defined below) private placements will enable us to fund our operating expenses and capital requirements through at least the next twelve months. Our estimate as to how long we expect the net proceeds from the Business Combination and the Private Placement these equity financings to be able to fund our operating expenses and capital requirements is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Changing circumstances, some of which may be beyond our control, could result in less cash available to us or cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned.

Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical drug products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:

- the extent to which we develop, in-license or acquire other product candidates and technologies in our product candidates pipeline;
- the costs and timing of process development and manufacturing scale-up activities associated with our product candidates and other programs as we advance them through preclinical and clinical development;

[Table of Contents](#)

- the number and development requirements of product candidates that we may pursue;
- the costs, timing and outcome of regulatory review of our product candidates;
- the timing and amount of our milestone payments to Pfizer under the Pfizer Agreement and to Lilly under the Lilly Licenses;
- our headcount growth and associated costs as we expand our research and development capabilities and establish and expand our commercial infrastructure and operations;
- the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distributions, for any of our product candidates for which we receive marketing approval;
- royalty payments to Pfizer under the Pfizer Agreement and Lilly under the Lilly Licenses;
- the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;
- the revenue, if any, received from sales of our product candidates for which we receive marketing approval; and
- the costs of operating as a public **company company**.

Identifying potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process that takes many years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of our product candidates that we do not expect to be commercially available in the near term, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the terms of these equity securities or this debt may restrict our ability to operate. Any future debt financing and equity financing, if available, may involve covenants limiting and restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, entering into profit-sharing or other arrangements or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise capital when needed or on

[Table of Contents](#)

acceptable terms, we could be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.

Cash Flows

	For the			
	For the	Period from	For the	For the
	Nine Months	January 18,	Three Months	Three Months
	Ended	2022 (date of	Ended	Ended
	September 30,	inception) to	March 31,	March 31,
	2023	September 30,	2024	2023
		2022		
Net cash used in operating activities	\$ (11,001)	\$ (1,593)	\$ (4,982)	\$ (3,257)
Net cash used in investing activities	(8,000)	(5,000)	(5,007)	—
Net cash provided by financing activities	121,293	9,642	—	45,653
Net increase in cash and cash equivalents	\$ 102,292	\$ 3,049		
Net increase/(decrease) in cash and cash equivalents			\$ (9,989)	\$ 42,396

Cash flows from operating activities

Cash used in operating activities for the **nine** **three** months ended **September 30, 2023** **March 31, 2024**, was **\$11.0 million** **\$4.9 million**, which consisted of a net loss before redeemable noncontrolling interest of **\$52.1 million** **\$7.7 million** and a net change of \$0.2 million in our net operating assets and liabilities, partially offset by \$3.0 million in non-cash charges. The non-cash charges consisted of expense from share-based compensation of \$2.4 million and a change in fair value on the private placement warrants of \$0.6 million, partially offset by **\$39.0 million** a nominal amount of foreign exchange transaction gains.

Cash used in operating activities for the three months ended March 31, 2023, was \$3.3 million, which consisted of a net loss before redeemable noncontrolling interest of \$9.8 million, partially offset by \$6.3 million in non-cash charges and a net change of **\$2.1 million** **\$0.2 million** in our net operating assets and liabilities. The non-cash charges consisted of expense **incurred in connection with** **from** the **2023 Lilly License** issuance of **\$27.4 million** convertible preferred shares to Pfizer under the anti-dilution provision of the Pfizer Agreement of **\$2.2 million**, a change in fair value of our promissory note of \$2.2 million, a change in fair value of our research and development license consideration liability of \$1.9 million, **share-based payment expense of \$2.2 million related to the anti-dilution**

37

[Table of Contents](#)

shares issued to Pfizer, additional share-based payments of **\$5.1 million**, **\$0.2 million** and a nominal amount of foreign exchange transaction losses partially offset by a change in fair value on the private placement warrants of \$0.2 million.

Cash used in operating activities for the period ended September 30, 2022 was \$1.6 million, which consisted of a net loss of \$9.8 million, partially offset by non-cash charges of \$7.8 million and a net change of \$0.4 million in our net operating assets and liabilities. The non-cash charges consisted of the \$7.5 million cost of the acquisition of the license under the Pfizer Agreement, which was expensed to research and development, and share-based payments of \$0.3 million.

Cash flows from investing activities

Cash used in investing activities for the **nine** **three** months ended **September 30, 2023** **March 31, 2024** was **\$8.0 million** **\$5.0 million**, which was **entirely** **primarily** related to the cash consideration paid to acquire the 2023 Lilly **License**. License as well as a nominal amount of equipment purchased during the period.

Cash **We did not have any net cash** used in **or provided by** investing activities for the **period** **three months** ended **September 30, 2022** was \$5.0 million, which was entirely related to the cash consideration paid to acquire the license from Pfizer under the Pfizer Agreement, **March 31, 2023**.

Cash flows from financing activities

We did not have any net cash used in or provided by financing activities for the three months ended March 31, 2024.

Cash provided by financing activities for the **nine** **three** months ended **September 30, 2023** **March 31, 2023**, was **\$121.3 million** **\$45.7 million**, which consisted of \$56.7 million of proceeds from the issuance of shares upon the closing of the Business Combination, and \$59.7 million of proceeds, net of transaction costs, from the issuance of Class A Ordinary Shares in connection with the April 2023 Private Placement, \$16.1 million of proceeds from the issuance of Pre-Funded Warrants in connection with the April 2023 Private Placement, partially offset by a \$10.0 million repayment of our promissory note and the payment of **\$1.2 million** of deferred transaction costs.

Cash provided by financing activities for the period ended September 30, 2022 was \$9.6 million, and was due to the issuance of \$10.0 million of Series A-1 convertible preferred shares of Legacy Zura in March 2022, partially offset by the payment of \$0.4 million **\$1.0 million** of deferred transaction costs.

Contractual Obligations and Other Commitments

We have or will enter into agreements in the normal course of business with contract research organizations, contract manufacturing organizations and other vendors for research and development services for operating purposes, which are generally cancelable upon written notice. Some third party CMOs have intellectual property, such as patents and/or know-how with an annual fee and royalty bearing license to its customers that forms part of the manufacturing agreement.

We have entered into the Lonza License for a worldwide non-exclusive license for Lonza's gene expression system in exchange for varying considerations depending on a number of factors such as whether the Company enters further into manufacturing agreements

[Table of Contents](#)

with Lonza or with a third party, and whether the Company enters into sublicense agreements with third parties (including up to middle six-figure annual payments per sublicense upon commencement of a sublicense, as well as royalties of up to low-single digit percentages of net sales of certain products over a commercially standard double-digit multi-year term). The Lonza License will remain in effect until terminated. The Company is free to terminate the Lonza License at any time upon 60 days' notice, with or without cause. Lonza may terminate the Lonza License for cause upon a breach by the Company or for other commercially standard reasons. During October 2023, the Company began drug substance manufacturing with a third party. As a result of manufacturing with a third party other than Lonza, under the terms of the Lonza License the first annual milestone payment of \$0.4 million became due and payable.

WuXi Biologics

In July 2023, we entered into a biologics master services agreement with WuXi Biologics (the "WuXi Biologics MSA") with WuXi Biologics. Under the WuXi Biologics MSA, we are obligated to pay WuXi Biologics a service fee and all non-cancellable obligations in the amount specified in each work order associated with the agreement for the provision of services. The People's Republic of China ("PRC"), and WuXi Biologics specifically, have faced increased scrutiny by the U.S. government, which could impact our ability to supply torudokimab as needed to meet our forecasted future demand.

The WuXi Biologics MSA terminates on the completion of services under all work orders executed by the parties, unless terminated earlier. The term of each work order terminates upon completion of the services under such work order, unless terminated earlier. We can terminate the WuXi Biologics MSA or any work order at any time upon 30 days' prior written notice and immediately upon written notice if WuXi Biologics fails to obtain or maintain required material governmental licenses or approvals. Either party may terminate a work order at any time upon three months' prior notice with reasonable cause, provided however that if WuXi Biologics terminates a

[Table of Contents](#)

work order in such manner, no termination or cancellation fees shall be paid by us and immediately for cause upon the other party's material breach that remains uncured for 30 days after notice of such breach.

In July 2023, we entered into a cell line license agreement (the "Cell Line License Agreement") with WuXi Biologics. The Cell Line License Agreement provides the Company with a non-exclusive, worldwide, sublicensable license to certain of WuXi Biologics' Biologics know-how, cell line, and biological materials (the "WuXi Biologics Licensed Technology") to manufacture, have manufactured, use, sell and import certain products produced through the use of the cell line licensed by WuXi Biologics under the Cell Line License Agreement (the "WuXi Biologics Licensed Products"). In consideration for the license, we agreed to pay WuXi Biologics a non-refundable license fee of \$150,000. Additionally, if we manufacture all of our commercial supplies of bulk drug product with a manufacturer other than WuXi Biologics or its affiliates, we are required to make royalty payments to WuXi Biologics in an amount equal to a fraction of a single digit percentage of global net sales of WuXi Biologics Licensed Products manufactured by a third-party manufacturer (the "Royalty"). If we manufacture part of our commercial supplies of the WuXi Biologics Licensed Products with WuXi Biologics or its affiliates, then the Royalty will be reduced accordingly on a pro rata basis.

The Cell Line License Agreement will continue indefinitely unless terminated (i) by us upon three months' prior written notice and its payment of all undisputed amounts due to WuXi Biologics through the effective date of termination, (ii) by WuXi Biologics for a material breach by us that remains uncured for 30 days after written notice, or (iii) by WuXi Biologics if we fail to make a payment and such failure continues for 30 days after receiving notice of such failure.

We have not included future milestone or royalty payments or other contractual payment obligations as the timing and amount of such obligations are unknown or uncertain and are contingent upon the initiation, continuation, and/or successful completion of future activities.

Critical Accounting Estimates

Management's discussion and analysis of our financial condition and results of operations is based on our unaudited interim condensed consolidated financial statements, which have been prepared in accordance with U.S. Generally Accepted Accounting Principles, Principles, and on a basis consistent with those accounting principles followed by us and disclosed in Note 2 to our most recent annual audited consolidated financial statements in the 2023 Annual Report. The preparation of these unaudited interim condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material.

31

[Table of Contents](#)

Other than as described under Note 2 of our unaudited interim condensed consolidated financial statements, there have been no material changes to our critical accounting policies from those described in "Management's Discussion and Analysis of Financial Condition and Results of Operations," included in our 2023 Annual Report.

Recent Accounting Pronouncements

See Note 2 to our unaudited condensed consolidated financial statements located in "Part I – Financial Information, Item 1. Financial Statements" in this Quarterly Report on Form 10-Q for a description of recent accounting pronouncements applicable to our financial statements.

Emerging Growth Company and Smaller Reporting Company Status

In April 2012, the JOBS Act was enacted. Section 107 of the JOBS Act provides that an "emerging growth company" can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. Upon closing of the Business Combination, we remained an emerging growth company and may elect to extend the transition period for complying with new or revised accounting standards, which delays the adoption of these accounting standards until they would apply to private companies.

In addition, as an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include:

- being permitted to present only two years of audited financial statements in addition to any required unaudited interim financial statements, with correspondingly reduced disclosure in the section titled "Management's Discussion and Analysis of Financial Condition and Results of Operations";

39

[Table of Contents](#)

- an exception from compliance with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended;
- reduced disclosure about our executive compensation arrangements in our periodic reports, proxy statements and registrations statements; and
- exemptions from the requirements of holding non-binding advisory votes on executive compensation or golden parachute arrangements; and an exemption from compliance with the requirements of the Public Company Accounting Oversight Board regarding the communication of critical audit matters in the auditor's report on financial statements.

We would cease to qualify as an emerging growth company on the date that is the earliest of: (i) December 31, 2026, (ii) the last day of the fiscal year in which we have more than \$1.07 billion in total annual gross revenues, (iii) the date on which we are deemed to be a “large accelerated filer” under the rules of the SEC, which means the market value of our Class A Ordinary Shares that is held by non-affiliates exceeds \$700.0 million as of the prior June 30th, or (iv) the date on which we have issued more than \$1.0 billion of non-convertible debt over the prior three-year period. We may choose to take advantage of some but not all of these reduced reporting burdens. We have taken advantage of certain reduced reporting requirements in this Quarterly report on Form 10-Q. Accordingly, the information contained herein may be different than you might obtain from other public companies in which you hold equity interests.

We are also a “smaller reporting company” as defined under the Securities Act and Exchange Act. We may continue to be a smaller reporting company so long as either (i) the market value of Class A Ordinary Shares held by non-affiliates is less than \$250 million or (ii) our annual revenue was less than \$100 million during the most recently completed fiscal year and the market value of Class A Ordinary Shares held by non-affiliates is less than \$700 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and have reduced disclosure obligations regarding executive compensation, and, similar to emerging growth companies, if we are a smaller reporting company under the requirements of (ii) above, we would not be required to obtain an attestation report on internal control over financial reporting issued by our independent registered public accounting firm.

32

[Table of Contents](#)

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As a “smaller reporting company”, as defined by Item 10 of Regulation S-K, we are not required permitted to provide the omit information otherwise required by this Item 3. item.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time period specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management including our Chief Executive Officer, Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. As of September 30, 2023 March 31, 2024, our Chief Executive Officer and Chief Financial Officer carried out an evaluation with the participation of management of the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of September 30, 2023 March 31, 2024.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Securities Exchange Act of 1934 that occurred during the quarter ended September 30, 2023 March 31, 2024, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

40

[Table of Contents](#)

Inherent Limitations on Effectiveness of Internal Controls

A control system, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the benefits of possible

controls and procedures relative to their costs. In addition, the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

41 33

[Table of Contents](#)

PART II

Item 1. Legal Proceedings

From time to time, we may become involved in litigation or other legal proceedings arising in the ordinary course of our business. We are not currently a party to any material litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors.

Item 1A. Risk Factors.

As a smaller reporting company, we are not required to make disclosures under this Item in our Quarterly Report on Form 10-Q.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

The securities issued in connection with the PIPE Subscription Agreements and Forward Purchase Agreement have not been registered under the Securities Act, in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act. **None.**

Item 3. Defaults upon Senior Securities

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

We are reporting the following information in lieu of reporting on a Current Report on Form 8-K under Item 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. **None.**

Resignation of Mr. Garry Neil

On November 3, 2023, Mr. Garry Neil notified Zura Bio Limited (the “Company”) of his resignation as a director of the Company, effective November 9, 2023. Mr. Neil has advised that his resignation was due to personal reasons and not a result of any disagreement with the Company on any matter related to the operations, policies, or practices of the Company.

Appointment of Mr. Arnout Ploos van Amstel as Director

To fill in the vacancy created by the resignation of Mr. Garry Neil, on November 9, 2023, the board of directors (the “Board”) of the Company appointed Mr. Arnout Ploos van Amstel to serve as an independent director of the Company, effective immediately. Mr. Arnout Ploos van Amstel will act as a member of the nominating and corporate governance committee.

There is no family relationship between Mr. Arnout Ploos van Amstel and any of our other officers and directors. To the best knowledge of the Company, there is no understanding or arrangement between Mr. Arnout Ploos van Amstel and any other person pursuant to which he was appointed as a director.

42

[Table of Contents](#)

Biographical Information of Arnout Ploos van Amstel

Mr. Arnout Ploos van Amstel, aged 58, is an executive leader in Life Sciences/Biotech with more than 30 years of business and operations experience in a wide variety of leadership positions and geographies. Arnout consistently excelled in devising and implementing comprehensive strategies across Development, Medical, and Commercial-Access domains. He founded Apaxcel Life Sciences GmbH in April 2019, a consulting company that supports biopharma customers in creating strategies that accelerate outcomes. He is currently serving as strategic consultant through Apaxcel Life Sciences GmbH. He is a founder of MoonLake Immunotherapeutics AG since January 2020, a biotech company dedicated to next-level therapies in inflammatory diseases. From July 2010 to March 2019, he worked as the President and Managing Director and then Senior Vice President for Novartis, leading its Global Business Unit Immunology/Dermatology where he achieved remarkable portfolio growth, notably with the success of COSENTYX® (secukinumab), XOLAIR® (omalizumab) for chronic spontaneous urticaria (CSU), and with the consistent growth of "orphan blockbuster" ILARIS® (canakinumab). Mr. Ploos van Amstel's experience includes leadership roles at Wyeth Pharmaceuticals and Novartis with executive positions in the US, Canada, Greece, the Netherlands and Switzerland. He was born and raised in the Netherlands and holds a Master's degree in Economics from the University of Groningen.

[Table of Contents](#)

Item 6. Exhibits.

The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q:

Exhibit Number	Description
10.1+	Employment Agreement between Zura Bio Limited and Robert Lisicki, (incorporated by reference to Exhibit 10.1 of the Company's Current Report on Form 8-K, filed with the SEC on January 8, 2024).
31.1*	Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**	Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**	Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	XBRL Instance Document*
101.SCH	XBRL Taxonomy Extension Schema Document*
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document*
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document*
101.LAB	XBRL Taxonomy Extension Label Linkbase Document*
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document*

* Filed herewith.

** Furnished herewith.

[Table of Contents](#)

SIGNATURES

Pursuant to the requirements of Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ZURA BIO LIMITED

Date: November 13, 2023 May 9, 2024

By: /s/ Someit Sidhu, MD Robert Lisicki

Name: Someit Sidhu, MD Robert Lisicki

Title: Chief Executive Officer
(Principal Executive Officer)

Date: November 13, 2023 May 9, 2024

By: /s/ Verender S. Badial

Name: Verender S. Badial

Title: Chief Financial Officer
(Principal Financial Officer)

EXHIBIT 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Someit Sidhu, Robert Lisicki, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Zura Bio Limited;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared; and

- b) (Paragraph omitted pursuant) Designed such internal control over financial reporting, or caused such internal control over financial reporting to Exchange Act Rules 13a-14(a) be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and 15d-15(a); the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
- a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 13, 2023

Date: May 9, 2024

/s/ Someit Sidhu Robert Lisicki

Someit Sidhu Robert Lisicki

Chief Executive Officer

(Principal Executive Officer)

EXHIBIT 31.2

**CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Verender Badial, certify that:

- 1. I have reviewed this quarterly report on Form 10-Q of Zura Bio Limited;
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared; and
 - b) (Paragraph omitted pursuant) Designed such internal control over financial reporting, or caused such internal control over financial reporting to Exchange Act Rules 13a-14(a) be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and 15d-15(a); the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

- c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
- a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 13, 2023

Date: May 9, 2024

/s/ Verender Badial

Verender Badial

Chief Financial Officer

(Principal Financial and Accounting Officer)

EXHIBIT 32.1

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Zura Bio Limited (the "Company") on Form 10-Q for the quarterly period ended September 30, 2023 March 31, 2024, as filed with the Securities and Exchange Commission (the "Report"), I, Someit Sidhu, Robert Lisicki, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 13, 2023 May 9, 2024

/s/ Someit Sidhu Robert Lisicki

Someit Sidhu Robert Lisicki

Chief Executive Officer

(Principal Executive Officer)

EXHIBIT 32.2

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Zura Bio Limited (the "Company") on Form 10-Q for the quarterly period ended **September 30, 2023** **March 31, 2024**, as filed with the Securities and Exchange Commission (the "Report"), I, Verender Badial, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: **November 13, 2023** **May 9, 2024**

/s/ Verender Badial

Verender Badial

Chief Financial Officer

(Principal Financial and Accounting Officer)

DISCLAIMER

THE INFORMATION CONTAINED IN THE REFINITIV CORPORATE DISCLOSURES DELTA REPORT™ IS A COMPARISON OF TWO FINANCIALS PERIODIC REPORTS. THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORT INCLUDING THE TEXT AND THE COMPARISON DATA AND TABLES. IN NO WAY DOES REFINITIV OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED IN THIS REPORT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S ACTUAL SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

©2024, Refinitiv. All rights reserved. Patents Pending.